<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEPAKOTE- divalproex sodium tablet, extended release </strong><br>Cardinal Health<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Depakote ER safely and effectively. See full prescribing information for Depakote ER.<br>Depakote ER (divalproex sodium) Tablet, Extended Release for Oral use<br>Initial U.S. Approval: 2000</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: LIFE THREATENING ADVERSE REACTIONS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Hepatotoxicity, including fatalities, usually during first 6 months of treatment. Children under the age of two years are at considerably higher risk of fatal hepatotoxicity. Monitor patients closely, and perform liver function tests prior to therapy and at frequent intervals thereafter<a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span>, including <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span><a href="#i4i_section_id_2340085c-20cb-4032-8ab5-e1621df12da0">(5.2)</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, including fatal hemorrhagic cases<a href="#i4i_section_id_87295897-6c45-4b22-a936-09cfdc513705">(5.3)</a></span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Warnings and Precautions <a href="#i4i_warnings_precautions_id_6e218074-0906-4954-9177-d372e1c9c284">(5.5) </a>4/2009 </p>
<p class="Highlighta">Warnings and Precautions <a href="#i4i_section_id_2340085c-20cb-4032-8ab5-e1621df12da0">(5.2)</a>  11/2009 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: LIFE THREATENING ADVERSE REACTIONS</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Hepatotoxicity, including fatalities, usually during first 6 months of treatment. Children under the age of two years are at considerably higher risk of fatal hepatotoxicity. Monitor patients closely, and perform liver function tests prior to therapy and at frequent intervals thereafter<a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span>, including <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span><a href="#i4i_section_id_2340085c-20cb-4032-8ab5-e1621df12da0">(5.2)</a></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, including fatal hemorrhagic cases<a href="#i4i_section_id_87295897-6c45-4b22-a936-09cfdc513705">(5.3)</a></span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Depakote ER is indicated for: </p>
<ul>
<li>Acute treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with bipolar disorder, with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features <a href="#i4i_section_id_8dd206ee-db19-4e03-a15a-adec7ac19628">(1.1)</a>
</li>
<li>Monotherapy and adjunctive therapy of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span> and simple and complex absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; adjunctive therapy in patients with multiple <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> types that include absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> <a href="#i4i_section_id_0bc4aa7a-45e3-41f6-9743-acb80c22bf62">(1.2)</a>
</li>
<li>Prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> <a href="#i4i_section_id_55b98525-c787-402d-8099-468358366e15">(1.3)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Depakote ER is intended for once-a-day oral administration. Depakote ER should be swallowed whole and should not be crushed or chewed. </li>
<li><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>: - Initial dose is 25 mg/kg/day,increasing as rapidly as possible to achieve therapeutic response or desired plasma level <a href="#i4i_section_id_344c0a99-70a3-4597-aabb-d4b6b2acbbd3">(2.1)</a>. The maximum recommended dosage is 60 mg/kg/day. <a href="#i4i_section_id_344c0a99-70a3-4597-aabb-d4b6b2acbbd3">(2.1</a>, <a href="#i4i_section_id_0bc4aa7a-45e3-41f6-9743-acb80c22bf62">2.2)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">Complex Partial Seizures</span>: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response; if response is not satisfactory, check valproate plasma level; see full prescribing information for conversion to monotherapy<a href="#i4i_section_id_0bc4aa7a-45e3-41f6-9743-acb80c22bf62">(2.2)</a>. The maximum recommended dosage is 60 mg/kg/day. <a href="#i4i_section_id_344c0a99-70a3-4597-aabb-d4b6b2acbbd3">(2.1</a>, <a href="#i4i_section_id_0bc4aa7a-45e3-41f6-9743-acb80c22bf62">2.2)</a>
</li>
<li>Absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: Start at 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day until <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control or limiting side effects <a href="#i4i_section_id_0bc4aa7a-45e3-41f6-9743-acb80c22bf62">(2.2)</a>. The maximum recommended dosage is 60 mg/kg/day. <a href="#i4i_section_id_344c0a99-70a3-4597-aabb-d4b6b2acbbd3">(2.1</a>, <a href="#i4i_section_id_0bc4aa7a-45e3-41f6-9743-acb80c22bf62">2.2)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span>: The recommended starting dose is 500 mg/day for 1 week, thereafter increasing to 1000 mg/day <a href="#i4i_section_id_36576dda-ca0f-4ace-bf9b-1bf648b1cd11">(2.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 250mg and 500mg <a href="#i4i_dosage_form_strength_id_1c03724a-8c50-4dc8-b60a-5cf18265df0c">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic disease</span> or significant hepatic dysfunction <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4</a>, <a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">5.1)</a>
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4</a>, <a href="#i4i_section_id_b7fc40ba-4036-4906-9b88-ee178b8889fa">5.10)</a>
</li>
<li>Urea cycle disorders <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4</a>, <a href="#i4i_section_id_e5b7aa14-da58-43cc-a3ff-18ab4fbc02da">5.4)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Hepatotoxicity; monitor liver function tests <a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a>
</li>
<li>Teratogenic effects; weigh Depakote ER benefits of use during pregnancy against risk to the fetus <a href="#i4i_section_id_2340085c-20cb-4032-8ab5-e1621df12da0">(5.2)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>; Depakote ER should ordinarily be discontinued <a href="#i4i_section_id_87295897-6c45-4b22-a936-09cfdc513705">(5.3)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> or ideation; Antiepileptic drugs, including Depakote ER, increase the risk of suicidal thoughts or behavior <a href="#i4i_section_id_9de861e6-1f23-489c-807a-c5dbf0c6dce2">(5.5)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>; monitor platelet counts and coagulation tests <a href="#i4i_section_id_100a0452-afcb-476f-bc60-34c271afa56e">(5.6)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span>; measure <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> level if unexplained <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or changes in mental status, and also with concomitant topiramate use; consider discontinuation of valproate therapy <a href="#i4i_section_id_e5b7aa14-da58-43cc-a3ff-18ab4fbc02da">(5.4</a>, <a href="#i4i_section_id_5b1d0c1a-d6c2-4b72-b1fb-4a66491ba9c5">5.7</a>, <a href="#i4i_section_id_ab85a9ea-31b3-454f-bb81-5b63a5937f6e">5.8)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span>; <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> has been reported during valproate therapy with or without associated <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>. This adverse reaction can also occur in patients using concomitant topiramate <a href="#i4i_section_id_fcfdd76e-e83d-4029-8b24-5e394b6669e2">(5.9)</a>
</li>
<li>Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>; discontinue Depakote ER <a href="#i4i_section_id_b7fc40ba-4036-4906-9b88-ee178b8889fa">(5.10)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> in the elderly can occur. Depakote ER dosage should be increased slowly and with regular monitoring for fluid and nutritional intake <a href="#i4i_section_id_8bf02a30-c935-4a01-b161-16abf6a30f7b">(5.12)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>Most common adverse reactions (reported &gt;5%) reported in adult studies are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>/blurred, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> <a href="#i4i_section_id_066c5604-45d9-4fc2-9196-aa3908d63a1c">(6.1</a>, <a href="#i4i_section_id_f6d1420a-a44b-45db-a3d5-7b7ee467548d">6.2</a>, <a href="#i4i_section_id_45057023-a8ac-4a6e-9bb7-6f5cb805097c">6.3</a>, <a href="#i4i_section_id_43e16ed3-e57c-4ccc-87e9-ad5d4440098a">6.4)</a>. </li>
<li>Most common, drug-related adverse reactions (reported &gt;5% and twice the rate of placebo) reported in the controlled pediatric <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> study are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, increased <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. </li>
</ul>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Abbott Laboratories at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, primidone, phenobarbital, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. Therefore increased monitoring of valproate and concomitant drug concentrations and dose adjustment is indicated whenever enzyme-inducing or inhibiting drugs are introduced or withdrawn <a href="#i4i_section_id_7be97647-d6b6-4c9f-8c9c-ef46dacb32f6">(7.1)</a>
</li>
<li>Aspirin, carbapenem antibiotics: Monitoring of valproate concentrations are recommended <a href="#i4i_section_id_7be97647-d6b6-4c9f-8c9c-ef46dacb32f6">(7.1)</a>
</li>
<li>Co-administration of valproate can affect the pharmacokinetics of other drugs (e.g. diazepam, ethosuximide, lamotrigine, phenytoin) by inhibiting their metabolism or protein binding displacement <a href="#i4i_section_id_d44d1fe2-9941-48a2-9d33-e999ba44c74d">(7.2)</a>
</li>
<li>Dosage adjustment of amitryptyline/nortryptyline, warfarin, and zidovudine may be necessary if used concomitantly with Depakote ER <a href="#i4i_section_id_d44d1fe2-9941-48a2-9d33-e999ba44c74d">(7.2)</a>
</li>
<li>Topiramate: <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> <a href="#i4i_section_id_ab85a9ea-31b3-454f-bb81-5b63a5937f6e">(5.8</a>, <a href="#i4i_section_id_af072911-efcf-4b71-a026-9104eaf27d59">7.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Depakote ER can cause congenital malformations including <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> <a href="#i4i_section_id_2340085c-20cb-4032-8ab5-e1621df12da0">(5.2</a>, <a href="#i4i_pregnancy_id_6eb9713e-4a45-46f3-8e7f-2946dfc43733">8.1)</a>
</li>
<li>Pediatric: Children under the age of two years are at considerably higher risk of fatal hepatotoxicity <a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1</a>, <a href="#i4i_pediatric_use_id_3bf472cd-2dc1-402c-a2ab-93a1a7904b94">8.4)</a>
</li>
<li>Geriatric: reduce starting dose; increase dosage more slowly; monitor fluid and nutritional intake, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <a href="#i4i_section_id_8bf02a30-c935-4a01-b161-16abf6a30f7b">(5.12</a>, <a href="#i4i_geriatric_use_id_dfc5ccad-2126-451f-bae4-839d09a81781">8.5)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">BOXED WARNING</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Conversion from Depakote to Depakote ER</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 General Dosing Advice</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hepatotoxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span>/Usage in Pregnancy</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Urea Cycle Disorders</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> associated with Concomitant Topiramate Use</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Multi-Organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Interaction with Carbapenem Antibiotics </a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> in the Elderly</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Monitoring: Drug Plasma Concentration</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Effect on Ketone and <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">Thyroid Function Tests</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Effect on HIV and CMV Viruses Replication</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></a></h2>
<h2><a href="#section-6.2" class="toc">6.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-6.3" class="toc">6.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Other Patient Populations</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effects of Co-Administered Drugs on Valproate Clearance</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effects of Valproate on Other Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Topiramate</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Effect of Disease</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Hepatotoxicity</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-15.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span>/Usage in Pregnancy</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Suicidal Thinking and Behavior</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6 <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span></a></h2>
<h2><a href="#section-15.7" class="toc">17.7 Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_1a90348b-3404-4dff-b650-5adada48858b"></a><a name="section-1"></a><p></p>
<h1>BOXED WARNING</h1>
<p class="First">WARNING: LIFE THREATENING ADVERSE REACTIONS</p>
<p>Hepatotoxicity</p>
<p><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> resulting in fatalities has occurred in patients receiving valproic acid and its derivatives. Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital <span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">metabolic disorders</span>, those with severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders accompanied by <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, and those with organic brain disease. When Depakote ER is used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.</p>
<p>These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, a loss of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control may also occur. Patients should be monitored closely for appearance of these symptoms. Liver function tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a>]</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span></p>
<p>Valproate can produce teratogenic effects such as <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> (e.g., <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span>). Accordingly, the use of Depakote ER in women of childbearing potential requires that the benefits of its use be weighed against the risk of injury to the fetus. This is especially important when the treatment of a spontaneously reversible condition not ordinarily associated with permanent injury or risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (e.g., <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>) is contemplated <span class="Italics">[see Warnings and Precautions<a href="#i4i_section_id_2340085c-20cb-4032-8ab5-e1621df12da0">(5.2)</a>]</span>.</p>
<p>An information sheet describing the teratogenic potential of valproate is available for patients <span class="Italics">[see Patient Counseling Information<a href="#i4i_info_patients_id_5a8b54cd-de98-4bfc-84c6-47c418a856f0">(17)</a>]</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></p>
<p>Cases of life-threatening <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> can be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> that require prompt medical evaluation. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_87295897-6c45-4b22-a936-09cfdc513705">(5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_eee2a63b-a060-4ca1-a941-6a30621d9c10"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8dd206ee-db19-4e03-a15a-adec7ac19628"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></h2>
<p class="First">Depakote ER is a valproate and is indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with bipolar disorder, with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features. A <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> is a distinct period of abnormally and persistently elevated, expansive, or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span> mood. Typical symptoms of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> include pressure of speech, motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, reduced need for sleep, flight of ideas, grandiosity, poor judgment, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, and possible <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>. A mixed episode is characterized by the criteria for a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in conjunction with those for a major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> (<span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>, loss of interest or pleasure in nearly all activities).</p>
<p>The efficacy of Depakote ER is based in part on studies of Depakote (divalproex sodium delayed release tablets) in this indication, and was confirmed in a 3-week trial with patients meeting DSM-IV TR criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed type, who were hospitalized for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> <span class="Italics">[see Clinical Studies <a href="#i4i_section_id_1031f88f-96df-47bf-9821-4a804331ea0e">(14.1)</a>]</span>.</p>
<p>The effectiveness of valproate for long-term use in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use Depakote ER for extended periods should continually reevaluate the long-term risk-benefits of the drug for the individual patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39700cce-f8bb-4143-be60-208dafdce872"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">Depakote ER is indicated as monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to the age of 10 years with <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span> that occur either in isolation or in association with other types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Depakote ER is also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in adults and children 10 years of age or older, and adjunctively in adults and children 10 years of age or older with multiple <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> types that include absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>Simple absence is defined as very brief clouding of the sensorium or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_55b98525-c787-402d-8099-468358366e15"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">Depakote ER is indicated for prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>. There is no evidence that Depakote ER is useful in the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>. Because it may be a hazard to the fetus, Depakote ER should be considered for women of childbearing potential only after this risk has been thoroughly discussed with the patient and weighed against the potential benefits of treatment <span class="Italics">[see Warnings and Precautions<a href="#i4i_section_id_2340085c-20cb-4032-8ab5-e1621df12da0">(5.2)</a>, Patient Counseling Information<a href="#i4i_section_id_8f90c172-2394-4794-9ea3-e40e542ef6d2">(17.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_a163aef9-2726-4b42-94d0-8a12e44dcdb3"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Depakote ER is an extended-release product intended for once-a-day oral administration. Depakote ER tablets should be swallowed whole and should not be crushed or chewed.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_344c0a99-70a3-4597-aabb-d4b6b2acbbd3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></h2>
<p class="First">Depakote ER tablets are administered orally. The recommended initial dose is 25 mg/kg/day given once daily. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose which produces the desired clinical effect or the desired range of plasma concentrations. In a placebo-controlled clinical trial of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> or mixed type, patients were dosed to a clinical response with a trough plasma concentration between 85 and 125 mcg/mL. The maximum recommended dosage is 60 mg/kg/day. </p>
<p>There is no body of evidence available from controlled trials to guide a clinician in the longer term management of a patient who improves during Depakote ER treatment of an acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span>. While it is generally agreed that pharmacological treatment beyond an acute response in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> is desirable, both for maintenance of the initial response and for prevention of new <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span>, there are no data to support the benefits of Depakote ER in such longer-term treatment (i.e., beyond 3 weeks).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0bc4aa7a-45e3-41f6-9743-acb80c22bf62"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">Depakote ER (divalproex sodium) extended release tablets are administered orally, and must be swallowed whole. As Depakote ER dosage is titrated upward, concentrations of clonazepam, diazepam, ethosuximide, lamotrigine, tolbutamide, phenobarbital, carbamazepine, and/or phenytoin may be affected <span class="Italics">[see Drug Interactions <a href="#i4i_section_id_d44d1fe2-9941-48a2-9d33-e999ba44c74d">(7.2)</a>]</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">Complex Partial Seizures</span> </span></p>
<p>For adults and children 10 years of age or older.</p>
<p><span class="Underline">Monotherapy (Initial Therapy)</span></p>
<p>Depakote ER has not been systematically studied as initial therapy. Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made.</p>
<p>The probability of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> increases significantly at total trough valproate plasma concentrations above 110 mcg/mL in females and 135 mcg/mL in males. The benefit of improved <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control with higher doses should be weighed against the possibility of a greater incidence of adverse reactions. </p>
<p><span class="Underline">Conversion to Monotherapy</span></p>
<p>Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made.</p>
<p>Concomitant antiepilepsy drug (AED) dosage can ordinarily be reduced by approximately 25% every 2 weeks. This reduction may be started at initiation of Depakote ER therapy, or delayed by 1 to 2 weeks if there is a concern that <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are likely to occur with a reduction. The speed and duration of withdrawal of the concomitant AED can be highly variable, and patients should be monitored closely during this period for increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency.</p>
<p><span class="Underline">Adjunctive Therapy</span></p>
<p>Depakote ER may be added to the patient's regimen at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made. </p>
<p>In a study of adjunctive therapy for <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span> in which patients were receiving either carbamazepine or phenytoin in addition to valproate, no adjustment of carbamazepine or phenytoin dosage was needed <span class="Italics">[see Clinical Studies<a href="#i4i_section_id_c8c356c2-2f41-4c41-9d4f-2fe0065c8386">(14.3)</a>]</span>. However, since valproate may interact with these or other concurrently administered AEDs as well as other drugs, periodic plasma concentration determinations of concomitant AEDs are recommended during the early course of therapy <span class="Italics">[see Drug Interactions<a href="#i4i_interactions_id_c6b6e770-d94f-4e73-b606-81a1bfe5c579">(7)</a>]</span>.</p>
<p><span class="Bold">Simple and Complex Absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></p>
<p>The recommended initial dose is 15 mg/kg/day, increasing at one week intervals by 5 to 10 mg/kg/day until <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are controlled or side effects preclude further increases. The maximum recommended dosage is 60 mg/kg/day. </p>
<p>A good correlation has not been established between daily dose, serum concentrations, and therapeutic effect. However, therapeutic valproate serum concentration for most patients with absence <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is considered to range from 50 to 100 mcg/mL. Some patients may be controlled with lower or higher serum concentrations <span class="Italics">[see Clinical Pharmacology<a href="#i4i_pharmacokinetics_id_ee4fa0c9-ba1b-4a6b-a720-f294d7f933ea">(12.3)</a>]</span>.</p>
<p>As Depakote ER dosage is titrated upward, blood concentrations of phenobarbital and/or phenytoin may be affected <span class="Italics">[see Drug Interactions<a href="#i4i_section_id_d44d1fe2-9941-48a2-9d33-e999ba44c74d">(7.2)</a>]</span>.</p>
<p>Antiepilepsy drugs should not be abruptly discontinued in patients in whom the drug is administered to prevent major <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> because of the strong possibility of precipitating <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> with attendant <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and threat to life.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_36576dda-ca0f-4ace-bf9b-1bf648b1cd11"></a><a name="section-2.3"></a><p></p>
<h2>2.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">Depakote ER is indicated for prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> in adults. </p>
<p>The recommended starting dose is 500 mg once daily for 1 week, thereafter increasing to 1000 mg once daily. Although doses other than 1000 mg once daily of Depakote ER have not been evaluated in patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, the effective dose range of Depakote (divalproex sodium delayed-release tablets) in these patients is 500-1000 mg/day. As with other valproate products, doses of Depakote ER should be individualized and dose adjustment may be necessary. If a patient requires smaller dose adjustments than that available with Depakote ER, Depakote should be used instead.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7f54e6e-baec-4f76-974d-8297407462fb"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Conversion from Depakote to Depakote ER</h2>
<p class="First">In adult patients and pediatric patients 10 years of age or older with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> previously receiving Depakote, Depakote ER should be administered once-daily using a dose 8 to 20% higher than the total daily dose of Depakote (Table 1). For patients whose Depakote total daily dose cannot be directly converted to Depakote ER, consideration may be given at the clinician’s discretion to increase the patient’s Depakote total daily dose to the next higher dosage before converting to the appropriate total daily dose of Depakote ER. </p>
<a name="id_0f060690-d7d6-43a6-a8b2-babbc1b72416"></a><table>
<caption><span>Table 1. Dose Conversion</span></caption>
<col width="50%">
<col width="50%">
<thead>
<tr class="First Toprule">
<td align="center" valign="top"><span class="Bold">Depakote</span></td>
<td align="center" valign="top"><span class="Bold">Depakote ER</span></td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top"><span class="Bold">Total Daily Dose (mg)</span></td>
<td align="center" valign="top"><span class="Bold">(mg)</span></td>
</tr>
</thead>
<tfoot><tr class="Last"><td align="left" colspan="2" valign="top"><p class="First">*   These total daily doses of Depakote cannot be directly converted to an 8 to 20% higher total daily dose of Depakote ER because the required dosing strengths of Depakote ER are not available. Consideration may be given at the clinician's discretion to increase the patient's Depakote total daily dose to the next higher dosage before converting to the appropriate total daily dose of Depakote ER.</p></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="center" valign="top">500* - 625</td>
<td align="center" valign="top">750</td>
</tr>
<tr>
<td align="center" valign="top">750* - 875</td>
<td align="center" valign="top">1000</td>
</tr>
<tr>
<td align="center" valign="top">1000*-1125</td>
<td align="center" valign="top">1250</td>
</tr>
<tr>
<td align="center" valign="top">1250-1375</td>
<td align="center" valign="top">1500</td>
</tr>
<tr>
<td align="center" valign="top">1500-1625</td>
<td align="center" valign="top">1750</td>
</tr>
<tr>
<td align="center" valign="top">1750</td>
<td align="center" valign="top">2000</td>
</tr>
<tr>
<td align="center" valign="top">1875-2000</td>
<td align="center" valign="top">2250</td>
</tr>
<tr>
<td align="center" valign="top">2125-2250</td>
<td align="center" valign="top">2500</td>
</tr>
<tr>
<td align="center" valign="top">2375</td>
<td align="center" valign="top">2750</td>
</tr>
<tr>
<td align="center" valign="top">2500-2750</td>
<td align="center" valign="top">3000</td>
</tr>
<tr>
<td align="center" valign="top">2875</td>
<td align="center" valign="top">3250</td>
</tr>
<tr class="Last">
<td align="center" valign="top">3000-3125</td>
<td align="center" valign="top">3500</td>
</tr>
</tbody>
</table>
<p>There is insufficient data to allow a conversion factor recommendation for patients with DEPAKOTE doses above 3125 mg/day. Plasma valproate Cmin concentrations for DEPAKOTE ER on average are equivalent to DEPAKOTE, but may vary across patients after conversion. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL) <span class="Italics">[see Clinical Pharmacology<a href="#i4i_pharmacodynamics_id_093f72f5-4852-42e5-85db-e4ac805f415a">(12.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e9f7370-d3b8-4736-8802-f7a81ece54ac"></a><a name="section-2.5"></a><p></p>
<h2>2.5 General Dosing Advice</h2>
<p class="First"><span class="Underline">Dosing in Elderly Patients</span></p>
<p>Due to a decrease in unbound clearance of valproate and possibly a greater sensitivity to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> in the elderly, the starting dose should be reduced in these patients. Starting doses in the elderly lower than 250mg can only be achieved by the use of Depakote. Dosage should be increased more slowly and with regular monitoring for fluid and nutritional intake, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and other adverse reactions. Dose reductions or discontinuation of valproate should be considered in patients with decreased food or fluid intake and in patients with excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. The ultimate therapeutic dose should be achieved on the basis of both tolerability and clinical response <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_8bf02a30-c935-4a01-b161-16abf6a30f7b">(5.12)</a>]</span>.</p>
<p><span class="Underline">Dose-Related Adverse Reactions</span></p>
<p>The frequency of adverse effects (particularly elevated liver enzymes and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) may be dose-related. The probability of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> appears to increase significantly at total valproate concentrations of ≥ 110 mcg/mL (females) or ≥ 135 mcg/mL (males) <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_100a0452-afcb-476f-bc60-34c271afa56e">(5.6)</a>]</span>. The benefit of improved therapeutic effect with higher doses should be weighed against the possibility of a greater incidence of adverse reactions.</p>
<p><span class="Underline">G.I. Irritation</span></p>
<p>Patients who experience G.I. irritation may benefit from administration of the drug with food or by slowly building up the dose from an initial low level.</p>
<p><span class="Underline">Compliance</span></p>
<p>Patients should be informed to take Depakote ER every day as prescribed. If a dose is missed it should be taken as soon as possible, unless it is almost time for the next dose. If a dose is skipped, the patient should not double the next dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_1c03724a-8c50-4dc8-b60a-5cf18265df0c"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Depakote ER 250 mg is available as white ovaloid tablets with the corporate Abbott “A? logo, and the Abbo-Code (HF). Each Depakote ER tablet contains divalproex sodium equivalent to 250 mg of valproic acid.</p>
<p>Depakote ER 500 mg is available as gray ovaloid tablets with the corporate Abbott “A? logo, and the Abbo-Code HC. Each Depakote ER tablet contains divalproex sodium equivalent to 500 mg of valproic acid. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul>
<li>Depakote ER should not be administered to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> or significant hepatic dysfunction <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a>].</span>
</li>
<li>Depakote ER is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_b7fc40ba-4036-4906-9b88-ee178b8889fa">(5.10)</a>].</span>
</li>
<li>Depakote ER is contraindicated in patients with known urea cycle disorders <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_e5b7aa14-da58-43cc-a3ff-18ab4fbc02da">(5.4)</a>].</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_6e218074-0906-4954-9177-d372e1c9c284"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hepatotoxicity</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> resulting in fatalities has occurred in patients receiving valproic acid. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, a loss of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control may also occur. Patients should be monitored closely for appearance of these symptoms. Liver function tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months. However, healthcare providers should not rely totally on serum biochemistry since these tests may not be abnormal in all instances, but should also consider the results of careful interim medical history and physical examination. </p>
<p>Caution should be observed when administering valproic acid products to patients with a prior history of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. Patients on multiple anticonvulsants, children, those with congenital <span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">metabolic disorders</span>, those with severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders accompanied by <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, and those with organic brain disease may be at particular risk. Experience has indicated that children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those with the aforementioned conditions. When Depakote ER is used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. Above this age group, experience in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> has indicated that the incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups. </p>
<p>The drug should be discontinued immediately in the presence of significant hepatic dysfunction, suspected or apparent. In some cases, hepatic dysfunction has progressed in spite of discontinuation of drug <span class="Italics">[see <a href="#i4i_warnings_precautions_id_6e218074-0906-4954-9177-d372e1c9c284">Boxed Warning</a> and Contraindications <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2340085c-20cb-4032-8ab5-e1621df12da0"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span>/Usage in Pregnancy</h2>
<p class="First">Use of Depakote ER during pregnancy can cause congenital malformations including <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Depakote ER should be considered for women of childbearing potential only after the risks have been thoroughly discussed with the patient and weighed against the potential benefits of treatment.</p>
<p>Data suggest that there is an increased incidence of congenital malformations associated with the use of valproate by women with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders during pregnancy when compared to the incidence in women with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders who do not use antiepileptic drugs during pregnancy, the incidence in women with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders who use other antiepileptic drugs, and the background incidence for the general population. </p>
<p>The data described below were gained almost exclusively from women who received valproate to treat <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. There are multiple reports in the clinical literature that indicate the use of antiepileptic drugs during pregnancy results in an increased incidence of congenital malformations in offspring. Antiepileptic drugs, including valproate, should be administered to women of childbearing potential only if they are clearly shown to be essential in the management of their medical condition.</p>
<p style="border-left:1px solid;"><span class="XmChange">There have been reports of <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span>, <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autism</span> and/or <span class="product-label-link" type="condition" conceptid="439776" conceptname="Pervasive developmental disorder">autism spectrum disorder</span> in the offspring of women exposed to valproate during pregnancy.</span></p>
<p>Antiepileptic drugs should not be discontinued abruptly in patients in whom the drug is administered to prevent major <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> because of the strong possibility of precipitating <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> with attendant <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and threat to life. In individual cases where the severity and frequency of the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> do not pose some hazard to the developing embryo or fetus <span class="Italics">[see <a href="#i4i_warnings_precautions_id_6e218074-0906-4954-9177-d372e1c9c284">Boxed Warning</a> and Use in Specific Populations <a href="#i4i_pregnancy_id_6eb9713e-4a45-46f3-8e7f-2946dfc43733">(8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_87295897-6c45-4b22-a936-09cfdc513705"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">Cases of life-threatening <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with rapid progression from initial symptoms to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Some cases have occurred shortly after initial use as well as after several years of use. The rate based upon the reported cases exceeds that expected in the general population and there have been cases in which <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> recurred after rechallenge with valproate. In clinical trials, there were 2 cases of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> without alternative etiology in 2416 patients, representing 1044 patient-years experience. Patients and guardians should be warned that <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> can be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> that require prompt medical evaluation. If <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> is diagnosed, Depakote ER should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated <span class="Italics">[see <a href="#i4i_warnings_precautions_id_6e218074-0906-4954-9177-d372e1c9c284">Boxed Warning</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e5b7aa14-da58-43cc-a3ff-18ab4fbc02da"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Urea Cycle Disorders</h2>
<p class="First">Depakote ER is contraindicated in patients with known urea cycle disorders (UCD). <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">Hyperammonemic encephalopathy</span>, sometimes fatal, has been reported following initiation of valproate therapy in patients with urea cycle disorders, a group of uncommon genetic abnormalities, particularly ornithine transcarbamylase deficiency. Prior to the initiation of Depakote ER therapy, evaluation for UCD should be considered in the following patients: 1) those with a history of unexplained <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> associated with a protein load, pregnancy-related or postpartum <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, unexplained <span class="product-label-link" type="condition" conceptid="440389" conceptname="Mental retardation">mental retardation</span>, or history of elevated plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> or glutamine; 2) those with cyclical <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, episodic extreme <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, low BUN, or protein avoidance; 3) those with a family history of UCD or a family history of unexplained infant <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (particularly males); 4) those with other signs or symptoms of UCD. Patients who develop symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> while receiving valproate therapy should receive prompt treatment (including discontinuation of valproate therapy) and be evaluated for underlying urea cycle disorders <span class="Italics">[see Contraindications <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4)</a> and Warnings and Precautions <a href="#i4i_section_id_5b1d0c1a-d6c2-4b72-b1fb-4a66491ba9c5">(5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9de861e6-1f23-489c-807a-c5dbf0c6dce2"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Antiepileptic drugs (AEDs), including Depakote ER, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Table 2 shows absolute and relative risk by indication for all evaluated AEDs.</span></p>
<a name="id_1c6a419c-8f57-4bd6-8d03-eed33f697a64"></a><table width="0.000">
<caption><span>Table 2. Risk by indication for antiepileptic drugs in the pooled analysis</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First Toprule">
<td align="center" valign="top"><span class="Bold">Indication</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Placebo Patients with Events Per 1000 Patients</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Drug Patients with Events Per 1000 Patients</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</span></td>
<td align="center" valign="top"><span class="Bold">Risk Difference: Additional Drug Patients with Events Per 1000 Patients</span></td>
</tr>
<tr>
<td align="center" valign="top"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></td>
<td align="center" valign="top">1.0</td>
<td align="center" valign="top">3.4</td>
<td align="center" valign="top">3.5</td>
<td align="center" valign="top">2.4</td>
</tr>
<tr>
<td align="center" valign="top">Psychiatric</td>
<td align="center" valign="top">5.7</td>
<td align="center" valign="top">8.5</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">2.9</td>
</tr>
<tr>
<td align="center" valign="top">Other</td>
<td align="center" valign="top">1.0</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">0.9</td>
</tr>
<tr class="Botrule Last">
<td align="center" valign="top">Total</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">4.3</td>
<td align="center" valign="top">1.8</td>
<td align="center" valign="top">1.9</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange">The relative risk for suicidal thoughts or behavior was higher in clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Anyone considering prescribing Depakote ER or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_100a0452-afcb-476f-bc60-34c271afa56e"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First">The frequency of adverse effects (particularly elevated liver enzymes and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) may be dose-related. In a clinical trial of valproate as monotherapy in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, 34/126 patients (27%) receiving approximately 50 mg/kg/day on average, had at least one value of platelets ≤ 75 x 10<span class="Sup">9</span>/L. Approximately half of these patients had treatment discontinued, with return of platelet counts to normal. In the remaining patients, platelet counts normalized with continued treatment. In this study, the probability of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> appeared to increase significantly at total valproate concentrations of ≥ 110 mcg/mL (females) or ≥ 135 mcg/mL (males). The therapeutic benefit which may accompany the higher doses should therefore be weighed against the possibility of a greater incidence of adverse effects.</p>
<p>Because of reports of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, inhibition of the secondary phase of platelet aggregation, and abnormal coagulation parameters, (e.g., low fibrinogen), platelet counts and coagulation tests are recommended before initiating therapy and at periodic intervals. It is recommended that patients receiving Depakote ER be monitored for platelet count and coagulation parameters prior to planned surgery. Evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, or a disorder of hemostasis/coagulation is an indication for reduction of the dosage or withdrawal of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b1d0c1a-d6c2-4b72-b1fb-4a66491ba9c5"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> has been reported in association with valproate therapy and may be present despite normal liver function tests. In patients who develop unexplained <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or changes in mental status, <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> should be considered and an <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> level should be measured. <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> should also be considered in patients who present with <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_fcfdd76e-e83d-4029-8b24-5e394b6669e2">(5.9)</a>]</span>. If <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> is increased, valproate therapy should be discontinued. Appropriate interventions for treatment of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> should be initiated, and such patients should undergo investigation for underlying urea cycle disorders <span class="Italics">[see Contraindications and Warnings and Precautions <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4</a>, <a href="#i4i_section_id_e5b7aa14-da58-43cc-a3ff-18ab4fbc02da">5.4</a>, <a href="#i4i_section_id_ab85a9ea-31b3-454f-bb81-5b63a5937f6e">5.8)</a>]</span>.</p>
<p>During the placebo controlled pediatric <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trial, one (1) in twenty (20) adolescents (5%) treated with valproate developed increased plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels compared to no (0) patients treated with placebo.</p>
<p>Asymptomatic elevations of <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> are more common and when present, require close monitoring of plasma <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels. If the elevation persists, discontinuation of valproate therapy should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab85a9ea-31b3-454f-bb81-5b63a5937f6e"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> associated with Concomitant Topiramate Use</h2>
<p class="First">Concomitant administration of topiramate and valproic acid has been associated with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with or without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> in patients who have tolerated either drug alone. Clinical symptoms of <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> often include acute alterations in level of consciousness and/or cognitive function with <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> can also be a manifestation of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_fcfdd76e-e83d-4029-8b24-5e394b6669e2">(5.9)</a>]</span>. In most cases, symptoms and signs abated with discontinuation of either drug. This adverse event is not due to a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>. It is not known if topiramate monotherapy is associated with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>. Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity may be at an increased risk for <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with or without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. Although not studied, an interaction of topiramate and valproic acid may exacerbate existing defects or unmask deficiencies in susceptible persons. In patients who develop unexplained <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or changes in mental status, <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> should be considered and an <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> level should be measured <span class="Italics">[see Contraindications <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4)</a> and Warnings and Precautions <a href="#i4i_section_id_5b1d0c1a-d6c2-4b72-b1fb-4a66491ba9c5">(5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fcfdd76e-e83d-4029-8b24-5e394b6669e2"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span>, defined as an unintentional drop in body core temperature to &lt; 35° C (95° F), has been reported in association with valproate therapy both in conjunction with and in the absence of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>. This adverse reaction can also occur in patients using concomitant topiramate with valproate after starting topiramate treatment or after increasing the daily dose of topiramate <span class="Italics">[see Drug Interactions <a href="#i4i_section_id_af072911-efcf-4b71-a026-9104eaf27d59">(7.3)</a>]</span>. Consideration should be given to stopping valproate in patients who develop <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, which may be manifested by a variety of clinical abnormalities including <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and significant alterations in other major organ systems such as the cardiovascular and respiratory systems. Clinical management and assessment should include examination of blood <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7fc40ba-4036-4906-9b88-ee178b8889fa"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Multi-Organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been rarely reported in close temporal association to the initiation of valproate therapy in adult and pediatric patients (median time to detection 21 days: range 1 to 40 days). Although there have been a limited number of reports, many of these cases resulted in hospitalization and at least one <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has been reported. Signs and symptoms of this disorder were diverse; however, patients typically, although not exclusively, presented with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with other organ system involvement. Other associated manifestations may include <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, liver function test abnormalities, hematological abnormalities (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, hepato-renal syndrome, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. Because the disorder is variable in its expression, other organ system symptoms and signs, not noted here, may occur. If this reaction is suspected, valproate should be discontinued and an alternative treatment started. Although the existence of cross sensitivity with other drugs that produce this syndrome is unclear, the experience amongst drugs associated with multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> would indicate this to be a possibility.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9ee9aa6-afb0-44ee-90b5-bff7ec14c82f"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Interaction with Carbapenem Antibiotics </h2>
<p class="First">Carbapenem antibiotics (ertapenem, imipenem, meropenem) may reduce serum valproic acid concentrations to subtherapeutic levels, resulting in loss of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or anticonvulsant therapy should be considered if serum valproic acid concentrations drop significantly or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control deteriorates <span class="Italics">[see Drug Interactions <a href="#i4i_section_id_7be97647-d6b6-4c9f-8c9c-ef46dacb32f6">(7.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8bf02a30-c935-4a01-b161-16abf6a30f7b"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> in the Elderly</h2>
<p class="First">In a double-blind, multicenter trial of valproate in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (mean age = 83 years), doses were increased by 125 mg/day to a target dose of 20 mg/kg/day. A significantly higher proportion of valproate patients had <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> compared to placebo, and although not statistically significant, there was a higher proportion of patients with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Discontinuations for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> were also significantly higher than with placebo. In some patients with <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (approximately one-half), there was associated reduced nutritional intake and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. There was a trend for the patients who experienced these events to have a lower baseline albumin concentration, lower valproate clearance, and a higher BUN. In elderly patients, dosage should be increased more slowly and with regular monitoring for fluid and nutritional intake, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and other adverse reactions. Dose reductions or discontinuation of valproate should be considered in patients with decreased food or fluid intake and in patients with excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <span class="Italics">[see Dosage and Administration<a href="#i4i_section_id_f7f54e6e-baec-4f76-974d-8297407462fb">(2.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_73ae58bc-b4e2-423f-9376-bc334a0c9f5c"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Monitoring: Drug Plasma Concentration</h2>
<p class="First">Since valproic acid may interact with concurrently administered drugs which are capable of enzyme induction, periodic plasma concentration determinations of valproate and concomitant drugs are recommended during the early course of therapy <span class="Italics">[see Drug Interactions <a href="#i4i_interactions_id_c6b6e770-d94f-4e73-b606-81a1bfe5c579">(7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e106096c-3bff-443c-8b30-24bcdfc0e1d2"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Effect on Ketone and <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">Thyroid Function Tests</span></h2>
<p class="First">Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test.</p>
<p>There have been reports of altered <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function tests</span> associated with valproate. The clinical significance of these is unknown. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b0d34adf-01eb-4ca6-8cb7-0e404ddf3a45"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Effect on HIV and CMV Viruses Replication</h2>
<p class="First">There are <span class="Italics">in vitro</span> studies that suggest valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions. The clinical consequence, if any, is not known. Additionally, the relevance of these <span class="Italics">in vitro</span> findings is uncertain for patients receiving maximally suppressive antiretroviral therapy. Nevertheless, these data should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_37c9acac-c721-4ab5-90c5-5bfad1a31061"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. </p>
<p>Information on pediatric adverse reactions is presented in section 8.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_066c5604-45d9-4fc2-9196-aa3908d63a1c"></a><a name="section-6.1"></a><p></p>
<h2>6.1 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></h2>
<p class="First">The incidence of treatment-emergent events has been ascertained based on combined data from two three week placebo-controlled clinical trials of Depakote ER in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> associated with bipolar disorder.</p>
<p>Table 3 summarizes those adverse reactions reported for patients in these trials where the incidence rate in the Depakote ER-treated group was greater than 5% and greater than the placebo incidence. </p>
<a name="id_9e2238df-97c2-43b1-af2e-3faa1f68d23c"></a><table border="1">
<caption><span>Table 3. Adverse Reactions Reported by &gt; 5% of Depakote-Treated Patients During Placebo-Controlled Trials of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Acute Mania</span><span class="Sup">1</span></span></caption>
<col width="97*">
<col width="98*">
<col width="101*">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"><span class="Bold">Adverse Event </span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold"> Depakote ER <br> (n=338)</span></td>
<td align="center" valign="top"><span class="Bold">Placebo <br>(n=263)</span></td>
</tr></thead>
<tfoot><tr class="Last"><td align="left" colspan="3" valign="top">1. The following adverse reactions/event occurred at an equal or greater incidence for placebo than for Depakote ER: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Toprule" align="center" valign="top">26%</td>
<td align="center" valign="top">14%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="top">23%</td>
<td align="center" valign="top">11%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">19%</td>
<td align="center" valign="top">13%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td align="center" valign="top">13%</td>
<td align="center" valign="top">5%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td align="center" valign="top">12%</td>
<td align="center" valign="top">8%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">12%</td>
<td align="center" valign="top">7%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </td>
<td align="center" valign="top">11%</td>
<td align="center" valign="top">10%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td align="center" valign="top">10%</td>
<td align="center" valign="top">5%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span></td>
<td align="center" valign="top">6%</td>
<td align="center" valign="top">5%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" valign="top">6%</td>
<td align="center" valign="top">5%</td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="center" valign="top">6%</td>
<td align="center" valign="top">5%</td>
</tr>
</tbody>
</table>
<p>The following additional adverse reactions were reported by greater than 1% but not more than 5% of the Depakote ER-treated patients in controlled clinical trials: </p>
<p><span class="Underline">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Infection Fungal</span></p>
<p><span class="Underline">Cardiovascular System:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p>
<p><span class="Underline">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p>
<p><span class="Underline">Hemic and Lymphatic System:</span> <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></p>
<p><span class="Underline">Metabolic and Nutritional Disorders</span> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></p>
<p><span class="Underline">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p>
<p><span class="Underline">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal Gait</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p>
<p><span class="Underline">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p>
<p><span class="Underline">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p>
<p><span class="Underline">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></p>
<p><span class="Underline">Urogenital System:</span> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f6d1420a-a44b-45db-a3d5-7b7ee467548d"></a><a name="section-6.2"></a><p></p>
<h2>6.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">Based on a placebo-controlled trial of adjunctive therapy for treatment of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span>, Depakote was generally well tolerated with most adverse reactions rated as mild to moderate in severity. Intolerance was the primary reason for discontinuation in the Depakote-treated patients (6%), compared to 1% of placebo-treated patients.</p>
<p>Table 4 lists treatment-emergent adverse reactions which were reported by ≥ 5% of Depakote-treated patients and for which the incidence was greater than in the placebo group, in the placebo-controlled trial of adjunctive therapy for treatment of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span>. Since patients were also treated with other antiepilepsy drugs, it is not possible, in most cases, to determine whether the following adverse reactions can be ascribed to Depakote alone, or the combination of Depakote and other antiepilepsy drugs.</p>
<a name="id_1f9d4a40-e6bf-4a19-bf9c-ec2ea03c48ec"></a><table>
<caption><span>Table 4. Adverse Reactions Reported by ≥ 5% of Patients Treated with Valproate During Placebo-Controlled Trial of Adjunctive Therapy for <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">Complex Partial Seizures</span></span></caption>
<col width="47%">
<col width="29%">
<col width="20%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"><span class="Bold">Body System/Event</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Depakote (%) <br>(N=77)</span></td>
<td align="center" valign="top"><span class="Bold">Placebo (%) <br>(N=70)</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule"><td align="left" colspan="3" valign="top"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">31</td>
<td align="center" valign="top">21</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" valign="top">27</td>
<td align="center" valign="top">7</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">4</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Gastrointestinal System </span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">48</td>
<td align="center" valign="top">14</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">27</td>
<td align="center" valign="top">7</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center" valign="top">23</td>
<td align="center" valign="top">6</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">13</td>
<td align="center" valign="top">6</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">1</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Nervous System</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">27</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center" valign="top">25</td>
<td align="center" valign="top">6</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">25</td>
<td align="center" valign="top">13</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span></td>
<td align="center" valign="top">16</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>/<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span></td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional Lability</span></td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">Thinking Abnormal</span></td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">1</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Respiratory System </span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span></td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">6</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">4</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Other</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">1</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span></td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<p>Table 5 lists treatment-emergent adverse reactions which were reported by ≥ 5% of patients in the high dose valproate group, and for which the incidence was greater than in the low dose group, in a controlled trial of Depakote monotherapy treatment of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span>. Since patients were being titrated off another antiepilepsy drug during the first portion of the trial, it is not possible, in many cases, to determine whether the following adverse reactions can be ascribed to Depakote alone, or the combination of valproate and other antiepilepsy drugs.</p>
<a name="id_aeb6b12f-d224-43c1-87f9-5ca85796212a"></a><table>
<caption><span>Table 5. Adverse Reactions Reported by ≥ 5% of Patients in the High Dose Group in the Controlled Trial of Valproate Monotherapy for <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">Complex Partial Seizures</span><span class="Sup">1</span></span></caption>
<col width="47%">
<col width="23%">
<col width="26%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"><span class="Bold">Body System/Event</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">High Dose (%) <br>(n=131)</span></td>
<td align="center" valign="top"><span class="Bold">Low Dose (%) <br>(n=134)</span></td>
</tr></thead>
<tfoot><tr class="Last"><td align="left" colspan="3" valign="top"><p class="First">1.   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> was the only adverse event that occurred in ≥5% of patients in the high dose group and at an equal or greater incidence in the low dose group.</p></td></tr></tfoot>
<tbody>
<tr class="First Toprule"><td align="left" colspan="3" valign="top"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">10</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Digestive System</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">34</td>
<td align="center" valign="top">26</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">23</td>
<td align="center" valign="top">19</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">23</td>
<td align="center" valign="top">15</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center" valign="top">11</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="top">11</td>
<td align="center" valign="top">10</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Hemic/Lymphatic System </span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center" valign="top">24</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">4</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Metabolic/Nutritional </span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">3</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Nervous System</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center" valign="top">57</td>
<td align="center" valign="top">19</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">30</td>
<td align="center" valign="top">18</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">18</td>
<td align="center" valign="top">13</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="top">15</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center" valign="top">11</td>
<td align="center" valign="top">7</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">4</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span></td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">4</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Respiratory System </span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="center" valign="top">20</td>
<td align="center" valign="top">13</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">2</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">1</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Skin and Appendages </span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="center" valign="top">24</td>
<td align="center" valign="top">13</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Special Senses</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">Amblyopia</span>/<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
<td align="center" valign="top">8</td>
<td align="center" valign="top">4</td>
</tr>
<tr class="Last">
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">1</td>
</tr>
</tbody>
</table>
<p>The following additional adverse reactions were reported by greater than 1% but less than 5% of the 358 patients treated with valproate in the controlled trials of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span>:</p>
<p><span class="Underline">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.</p>
<p><span class="Underline">Cardiovascular System: </span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>.</p>
<p><span class="Underline">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4103655" conceptname="Dental abscess">periodontal abscess</span>.</p>
<p><span class="Underline">Hemic and Lymphatic System:</span> <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechia</span>.</p>
<p><span class="Underline">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased, SGPT increased.</p>
<p><span class="Underline">Musculoskeletal System: </span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>.</p>
<p><span class="Underline">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>.</p>
<p><span class="Underline">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p><span class="Underline">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>.</p>
<p><span class="Underline">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>.</p>
<p><span class="Underline">Urogenital System:</span> <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_45057023-a8ac-4a6e-9bb7-6f5cb805097c"></a><a name="section-6.3"></a><p></p>
<h2>6.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">Based on two placebo-controlled clinical trials and their long term extension, valproate was generally well tolerated with most adverse reactions rated as mild to moderate in severity. Of the 202 patients exposed to valproate in the placebo-controlled trials, 17% discontinued for intolerance. This is compared to a rate of 5% for the 81 placebo patients. Including the long term extension study, the adverse reactions reported as the primary reason for discontinuation by ≥ 1% of 248 valproate-treated patients were <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> (6%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (5%), <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (2%), <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> (2%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1%), elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and/or SGPT (1%), and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (1%).</p>
<p>Table 6 includes those adverse reactions reported for patients in the placebo-controlled trial where the incidence rate in the Depakote ER-treated group was greater than 5% and was greater than that for placebo patients. </p>
<a name="id_62a7363b-0fe0-4342-ba52-4b5e09263a89"></a><table>
<caption><span>Table 6. Adverse Reactions Reported by &gt;5% of Depakote ER-Treated Patients During the <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Placebo-controlled Trial with a Greater Incidence than Patients Taking Placebo<span class="Sup">1</span></span></caption>
<col width="35%">
<col width="30%">
<col width="34%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top">
<span class="Bold">Body System</span><br><span class="Bold">Event</span>
</td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Depakote ER <br>(n=122)</span></td>
<td align="center" valign="top"><span class="Bold">Placebo <br>(n=115)</span></td>
</tr></thead>
<tfoot><tr class="Last"><td align="left" colspan="3" valign="top"><p class="First">1.   The following adverse reactions occurred in greater than 5% of Depakote ER-treated patients and at a greater incidence for placebo than for Depakote ER: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> and <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>.</p></td></tr></tfoot>
<tbody>
<tr class="First Toprule"><td align="left" colspan="3" valign="top"><span class="Bold">Gastrointestinal System </span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">15%</td>
<td align="center" valign="top">9%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="top">7%</td>
<td align="center" valign="top">4%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">7%</td>
<td align="center" valign="top">3%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">7%</td>
<td align="center" valign="top">2%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center" valign="top">7%</td>
<td align="center" valign="top">5%</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Nervous System</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">7%</td>
<td align="center" valign="top">2%</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Other</span></td></tr>
<tr class="Last">
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="center" valign="top">15%</td>
<td align="center" valign="top">14%</td>
</tr>
</tbody>
</table>
<p>The following additional adverse reactions were reported by greater than 1% but not more than 5% of Depakote ER-treated patients and with a greater incidence than placebo in the placebo-controlled clinical trial for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis:</p>
<p><span class="Underline">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>.</p>
<p><span class="Underline">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span>.</p>
<p><span class="Underline">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p><span class="Underline">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Underline">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.</p>
<p><span class="Underline">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>.</p>
<p><span class="Underline">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>.</p>
<p>Table 7 includes those adverse reactions reported for patients in the placebo-controlled trials where the incidence rate in the valproate-treated group was greater than 5% and was greater than that for placebo patients.</p>
<a name="id_dbb592f3-7573-4ae3-a77b-494248f4448b"></a><table>
<caption><span>Table 7. Adverse Reactions Reported by &gt; 5% of Valproate-Treated Patients During <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Placebo-Controlled Trials with a Greater Incidence than Patients Taking Placebo<span class="Sup">1</span></span></caption>
<col width="37%">
<col width="30%">
<col width="30%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top">
<span class="Bold">Body System</span><br><span class="Bold">Reaction</span>
</td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Depakote <br>(n=202)</span></td>
<td align="center" valign="top"><span class="Bold">Placebo <br>(n=81)</span></td>
</tr></thead>
<tfoot><tr class="Last"><td align="left" colspan="3" valign="top"><p class="First">1.   The following adverse reactions occurred in greater than 5% of Depakote-treated patients and at a greater incidence for placebo than for Depakote: <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span> and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>.</p></td></tr></tfoot>
<tbody>
<tr class="First Toprule"><td align="left" colspan="3" valign="top"><span class="Bold">Gastrointestinal System</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">31%</td>
<td align="center" valign="top">10%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="top">13%</td>
<td align="center" valign="top">9%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">12%</td>
<td align="center" valign="top">7%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">11%</td>
<td align="center" valign="top">1%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center" valign="top">9%</td>
<td align="center" valign="top">4%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td align="center" valign="top">6%</td>
<td align="center" valign="top">4%</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Nervous System</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center" valign="top">20%</td>
<td align="center" valign="top">9%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">17%</td>
<td align="center" valign="top">5%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">12%</td>
<td align="center" valign="top">6%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center" valign="top">9%</td>
<td align="center" valign="top">0%</td>
</tr>
<tr><td align="left" colspan="3" valign="top"><span class="Bold">Other</span></td></tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></td>
<td align="center" valign="top">8%</td>
<td align="center" valign="top">2%</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center" valign="top">8%</td>
<td align="center" valign="top">6%</td>
</tr>
<tr class="Last">
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="center" valign="top">7%</td>
<td align="center" valign="top">1%</td>
</tr>
</tbody>
</table>
<p>The following additional adverse reactions were reported by greater than 1% but not more than 5% of the 202 valproate-treated patients in the controlled clinical trials: </p>
<p><span class="Underline">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>.</p>
<p><span class="Underline">Cardiovascular System:</span> <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span>.</p>
<p><span class="Underline">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>.</p>
<p><span class="Underline">Hemic and Lymphatic System:</span> <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>.</p>
<p><span class="Underline">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>.</p>
<p><span class="Underline">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg cramps</span>.</p>
<p><span class="Underline">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, speech disorder, and thinking abnormalities.</p>
<p><span class="Underline">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.</p>
<p><span class="Underline">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>.</p>
<p><span class="Underline">Urogenital System:</span> <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">Metrorrhagia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43e16ed3-e57c-4ccc-87e9-ad5d4440098a"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Other Patient Populations</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p>The following adverse reactions not listed previously were reported by greater than 1% of Depakote-treated patients and with a greater incidence than placebo in placebo-controlled trials of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span> associated with bipolar disorder:</p>
<p><span class="Underline">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, drug level increased, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>.</p>
<p><span class="Underline">Cardiovascular System:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
<p><span class="Underline">Digestive System:</span> <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gum hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>.</p>
<p><span class="Underline">Hemic and Lymphatic System:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> increased, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span>.</p>
<p><span class="Underline">Metabolic and Nutritional Disorders:</span> <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">Hypoproteinemia</span>.</p>
<p><span class="Underline">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthrosis</span>.</p>
<p><span class="Underline">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="4011620" conceptname="Catatonic reaction">catatonic reaction</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">reflexes increased</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>.</p>
<p><span class="Underline">Respiratory System:</span> <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccup</span>.</p>
<p><span class="Underline">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="4066824" conceptname="Discoid lupus erythematosus">Discoid lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>.</p>
<p><span class="Underline">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorder</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>.</p>
<p><span class="Underline">Urogenital System:</span> <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></p>
<p>Adverse reactions that have been reported with all dosage forms of valproate from <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials, spontaneous reports, and other sources are listed below by body system.</p>
<p><span class="Underline">Gastrointestinal</span></p>
<p>The most commonly reported side effects at the initiation of therapy are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>. These effects are usually transient and rarely require discontinuation of therapy. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> have been reported. Both <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> with some <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> and <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span> with <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> have also been reported. In some patients, many of whom have functional or anatomic (including ileostomy or colostomy) <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> with shortened GI transit times, there have been postmarketing reports of Depakote ER tablets in stool. </p>
<p><span class="Underline">CNS Effects</span></p>
<p>Sedative effects have occurred in patients receiving valproate alone but occur most often in patients receiving combination therapy. Sedation usually abates upon reduction of other antiepileptic medication. <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> (may be dose-related), <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4138992" conceptname="Asterixis">asterixis</span>, "<span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">spots before eyes</span>", <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, and <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> have been reported with the use of valproate. Rare cases of <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> have occurred in patients receiving valproate alone or in conjunction with phenobarbital. In rare instances <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> with or without <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> has developed shortly after the introduction of valproate monotherapy without evidence of hepatic dysfunction or inappropriately high plasma valproate levels. Although recovery has been described following drug withdrawal, there have been fatalities in patients with <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span>, particularly in patients with underlying urea cycle disorders <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_e5b7aa14-da58-43cc-a3ff-18ab4fbc02da">(5.4)</a>]</span>.</p>
<p>Several reports have noted reversible <span class="product-label-link" type="condition" conceptid="4150603" conceptname="Cerebral atrophy">cerebral atrophy</span> and <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in association with valproate therapy.</p>
<p><span class="Underline">Dermatologic</span></p>
<p>Transient <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">generalized pruritus</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported including a fatal case in a 6 month old infant taking valproate and several other concomitant medications. An additional case of toxic epidermal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was reported in a 35 year old patient with AIDS taking several concomitant medications and with a history of multiple cutaneous drug reactions. Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been reported with concomitant administration of lamotrigine and valproate <span class="Italics">[see Drug Interactions<a href="#i4i_interactions_id_c6b6e770-d94f-4e73-b606-81a1bfe5c579">(7)</a>]</span>.</p>
<p><span class="Underline">Psychiatric</span></p>
<p>Emotional upset, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, and behavioral deterioration.</p>
<p><span class="Underline">Musculoskeletal</span></p>
<p><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>.</p>
<p><span class="Underline">Hematologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> and inhibition of the secondary phase of platelet aggregation may be reflected in altered <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> formation, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and frank <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_100a0452-afcb-476f-bc60-34c271afa56e">(5.6)</a> and Drug Interactions<a href="#i4i_interactions_id_c6b6e770-d94f-4e73-b606-81a1bfe5c579">(7)</a>]</span>. Relative <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span>, <span class="product-label-link" type="condition" conceptid="4125644" conceptname="Hypofibrinogenemia">hypofibrinogenemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> including macrocytic with or without <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>, bone marrow suppression, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span>.</p>
<p><span class="Underline">Hepatic</span></p>
<p>Minor elevations of transaminases (e.g., <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and SGPT) and LDH are frequent and appear to be dose-related. Occasionally, laboratory test results include increases in serum bilirubin and abnormal changes in other liver function tests. These results may reflect potentially serious hepatotoxicity <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a>]</span>.</p>
<p><span class="Underline">Endocrine</span></p>
<p>Irregular menses, secondary <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, and parotid gland <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>. Abnormal <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function tests</span> <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_73ae58bc-b4e2-423f-9376-bc334a0c9f5c">(5.13)</a>]</span>.</p>
<p>There have been rare spontaneous reports of <span class="product-label-link" type="condition" conceptid="195501" conceptname="Polycystic ovaries">polycystic ovary</span> disease. A cause and effect relationship has not been established.</p>
<p><span class="Underline">Pancreatic</span></p>
<p><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span> including fatalities <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_87295897-6c45-4b22-a936-09cfdc513705">(5.3)</a>]</span>.</p>
<p><span class="Underline">Metabolic</span></p>
<p><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_5b1d0c1a-d6c2-4b72-b1fb-4a66491ba9c5">(5.7)</a>]</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, and <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate ADH secretion</span>.</p>
<p>There have been rare reports of Fanconi's syndrome occurring chiefly in children.</p>
<p>Decreased carnitine concentrations have been reported although the clinical relevance is undetermined.</p>
<p>Hyperglycinemia has occurred and was associated with a fatal outcome in a patient with preexistent nonketotic hyperglycinemia.</p>
<p><span class="Underline">Genitourinary</span></p>
<p><span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Enuresis</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.</p>
<p><span class="Underline">Special Senses</span></p>
<p><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span>, either reversible or irreversible, has been reported; however, a cause and effect relationship has not been established. <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Ear pain</span> has also been reported.</p>
<p><span class="Underline">Other</span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the extremities, <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_c6b6e770-d94f-4e73-b606-81a1bfe5c579"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7be97647-d6b6-4c9f-8c9c-ef46dacb32f6"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effects of Co-Administered Drugs on Valproate Clearance</h2>
<p class="First">Drugs that affect the level of expression of hepatic enzymes, particularly those that elevate levels of glucuronosyltransferases, may increase the clearance of valproate. For example, phenytoin, carbamazepine, and phenobarbital (or primidone) can double the clearance of valproate. Thus, patients on monotherapy will generally have longer half-lives and higher concentrations than patients receiving polytherapy with antiepilepsy drugs. </p>
<p>In contrast, drugs that are inhibitors of cytochrome P450 isozymes, e.g., antidepressants, may be expected to have little effect on valproate clearance because cytochrome P450 microsomal mediated oxidation is a relatively minor secondary metabolic pathway compared to glucuronidation and beta-oxidation. </p>
<p>Because of these changes in valproate clearance, monitoring of valproate and concomitant drug concentrations should be increased whenever enzyme inducing drugs are introduced or withdrawn.</p>
<p>The following list provides information about the potential for an influence of several commonly prescribed medications on valproate pharmacokinetics. The list is not exhaustive nor could it be, since new interactions are continuously being reported. </p>
<p><span class="Underline">Drugs for which a potentially important interaction has been observed</span></p>
<p><span class="Italics">Aspirin</span></p>
<p>A study involving the co-administration of aspirin at antipyretic doses (11 to 16 mg/kg) with valproate to pediatric patients (n=6) revealed a decrease in protein binding and an inhibition of metabolism of valproate. Valproate free fraction was increased 4-fold in the presence of aspirin compared to valproate alone. The β-oxidation pathway consisting of 2-E-valproic acid, 3-OH-valproic acid, and 3-keto valproic acid was decreased from 25% of total metabolites excreted on valproate alone to 8.3% in the presence of aspirin. Whether or not the interaction observed in this study applies to adults is unknown, but caution should be observed if valproate and aspirin are to be co-administered.</p>
<p><span class="Italics">Carbapenem antibiotics</span></p>
<p>A clinically significant reduction in serum valproic acid concentration has been reported in patients receiving carbapenem antibiotics (ertapenem, imipenem, meropenem) and may result in loss of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control. The mechanism of this interaction in not well understood. Serum valproic acid concentrations should be monitored frequently after initiating carbapenem therapy. Alternative antibacterial or anticonvulsant therapy should be considered if serum valproic acid concentrations drop significantly or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control deteriorates <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_e9ee9aa6-afb0-44ee-90b5-bff7ec14c82f">(5.11)</a>]</span>.</p>
<p><span class="Italics">Felbamate</span></p>
<p>A study involving the co-administration of 1200 mg/day of felbamate with valproate to patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (n=10) revealed an increase in mean valproate peak concentration by 35% (from 86 to 115 mcg/mL) compared to valproate alone. Increasing the felbamate dose to 2400 mg/day increased the mean valproate peak concentration to 133 mcg/mL (another 16% increase). A decrease in valproate dosage may be necessary when felbamate therapy is initiated.</p>
<p><span class="Italics">Rifampin</span></p>
<p>A study involving the administration of a single dose of valproate (7 mg/kg) 36 hours after 5 nights of daily dosing with rifampin (600 mg) revealed a 40% increase in the oral clearance of valproate. Valproate dosage adjustment may be necessary when it is co-administered with rifampin.</p>
<p><span class="Underline">Drugs for which either no interaction or a likely clinically unimportant interaction has been observed</span></p>
<p><span class="Italics">Antacids</span></p>
<p>A study involving the co-administration of valproate 500 mg with commonly administered antacids (Maalox, Trisogel, and Titralac - 160 mEq doses) did not reveal any effect on the extent of absorption of valproate.</p>
<p><span class="Italics">Chlorpromazine</span></p>
<p>A study involving the administration of 100 to 300 mg/day of chlorpromazine to schizophrenic patients already receiving valproate (200 mg BID) revealed a 15% increase in trough plasma levels of valproate.</p>
<p><span class="Italics">Haloperidol</span></p>
<p>A study involving the administration of 6 to 10 mg/day of haloperidol to schizophrenic patients already receiving valproate (200 mg BID) revealed no significant changes in valproate trough plasma levels.</p>
<p><span class="Italics">Cimetidine and Ranitidine</span></p>
<p>Cimetidine and ranitidine do not affect the clearance of valproate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d44d1fe2-9941-48a2-9d33-e999ba44c74d"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effects of Valproate on Other Drugs</h2>
<p class="First">Valproate has been found to be a weak inhibitor of some P450 isozymes, epoxide hydrase, and glucuronosyltransferases.</p>
<p>The following list provides information about the potential for an influence of valproate co-administration on the pharmacokinetics or pharmacodynamics of several commonly prescribed medications. The list is not exhaustive, since new interactions are continuously being reported.</p>
<p><span class="Underline">Drugs for which a potentially important valproate interaction has been observed</span></p>
<p><span class="Italics">Amitriptyline/Nortriptyline</span></p>
<p>Administration of a single oral 50 mg dose of amitriptyline to 15 normal volunteers (10 males and 5 females) who received valproate (500 mg BID) resulted in a 21% decrease in plasma clearance of amitriptyline and a 34% decrease in the net clearance of nortriptyline. Rare postmarketing reports of concurrent use of valproate and amitriptyline resulting in an increased amitriptyline level have been received. Concurrent use of valproate and amitriptyline has rarely been associated with toxicity. Monitoring of amitriptyline levels should be considered for patients taking valproate concomitantly with amitriptyline. Consideration should be given to lowering the dose of amitriptyline/nortriptyline in the presence of valproate.</p>
<p><span class="Italics">Carbamazepine/carbamazepine-10,11-Epoxide</span></p>
<p>Serum levels of carbamazepine (CBZ) decreased 17% while that of carbamazepine-10,11-epoxide (CBZ-E) increased by 45% upon co-administration of valproate and CBZ to epileptic patients.</p>
<p><span class="Italics">Clonazepam</span></p>
<p>The concomitant use of valproic acid and clonazepam may induce absence status in patients with a history of absence type <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p><span class="Italics">Diazepam</span></p>
<p>Valproate displaces diazepam from its plasma albumin binding sites and inhibits its metabolism. Co-administration of valproate (1500 mg daily) increased the free fraction of diazepam (10 mg) by 90% in healthy volunteers (n=6). Plasma clearance and volume of distribution for free diazepam were reduced by 25% and 20%, respectively, in the presence of valproate. The elimination half-life of diazepam remained unchanged upon addition of valproate.</p>
<p><span class="Italics">Ethosuximide</span></p>
<p>Valproate inhibits the metabolism of ethosuximide. Administration of a single ethosuximide dose of 500 mg with valproate (800 to 1600 mg/day) to healthy volunteers (n=6) was accompanied by a 25% increase in elimination half-life of ethosuximide and a 15% decrease in its total clearance as compared to ethosuximide alone. Patients receiving valproate and ethosuximide, especially along with other anticonvulsants, should be monitored for alterations in serum concentrations of both drugs.</p>
<p><span class="Italics">Lamotrigine</span></p>
<p>In a steady-state study involving 10 healthy volunteers, the elimination half-life of lamotrigine increased from 26 to 70 hours with valproate co-administration (a 165% increase). The dose of lamotrigine should be reduced when co-administered with valproate. Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (such as Stevens - Johnson syndrome and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) have been reported with concomitant lamotrigine and valproate administration. See lamotrigine package insert for details on lamotrigine dosing with concomitant valproate administration.</p>
<p><span class="Italics">Phenobarbital</span></p>
<p>Valproate was found to inhibit the metabolism of phenobarbital. Co-administration of valproate (250 mg BID for 14 days) with phenobarbital to normal subjects (n=6) resulted in a 50% increase in half-life and a 30% decrease in plasma clearance of phenobarbital (60 mg single-dose). The fraction of phenobarbital dose excreted unchanged increased by 50% in presence of valproate. </p>
<p>There is evidence for severe <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, with or without significant elevations of barbiturate or valproate serum concentrations. All patients receiving concomitant barbiturate therapy should be closely monitored for neurological toxicity. Serum barbiturate concentrations should be obtained, if possible, and the barbiturate dosage decreased, if appropriate.</p>
<p>Primidone, which is metabolized to a barbiturate, may be involved in a similar interaction with valproate.</p>
<p><span class="Italics">Phenytoin</span></p>
<p>Valproate displaces phenytoin from its plasma albumin binding sites and inhibits its hepatic metabolism. Co-administration of valproate (400 mg TID) with phenytoin (250 mg) in normal volunteers (n=7) was associated with a 60% increase in the free fraction of phenytoin. Total plasma clearance and apparent volume of distribution of phenytoin increased 30% in the presence of valproate. Both the clearance and apparent volume of distribution of free phenytoin were reduced by 25%. </p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, there have been reports of breakthrough <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurring with the combination of valproate and phenytoin. The dosage of phenytoin should be adjusted as required by the clinical situation.</p>
<p><span class="Italics">Tolbutamide</span></p>
<p>From <span class="Italics">in vitro</span> experiments, the unbound fraction of tolbutamide was increased from 20% to 50% when added to plasma samples taken from patients treated with valproate. The clinical relevance of this displacement is unknown.</p>
<p><span class="Italics">Warfarin</span></p>
<p>In an <span class="Italics">in vitro</span> study, valproate increased the unbound fraction of warfarin by up to 32.6%. The therapeutic relevance of this is unknown; however, coagulation tests should be monitored if valproic acid therapy is instituted in patients taking anticoagulants.</p>
<p><span class="Italics">Zidovudine</span></p>
<p> In six patients who were seropositive for HIV, the clearance of zidovudine (100 mg q8h) was decreased by 38% after administration of valproate (250 or 500 mg q8h); the half-life of zidovudine was unaffected.</p>
<p><span class="Underline">Drugs for which either no interaction or a likely clinically unimportant interaction has been observed</span></p>
<p><span class="Italics">Acetaminophen</span></p>
<p>Valproate had no effect on any of the pharmacokinetic parameters of acetaminophen when it was concurrently administered to three epileptic patients.</p>
<p><span class="Italics">Clozapine</span></p>
<p>In <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> patients (n=11), no interaction was observed when valproate was co-administered with clozapine.</p>
<p><span class="Italics">Lithium</span></p>
<p>Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n=16) had no effect on the steady-state kinetics of lithium.</p>
<p><span class="Italics">Lorazepam</span></p>
<p>Concomitant administration of valproate (500 mg BID) and lorazepam (1 mg BID) in normal male volunteers (n=9) was accompanied by a 17% decrease in the plasma clearance of lorazepam.</p>
<p><span class="Italics">Oral Contraceptive Steroids</span></p>
<p>Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af072911-efcf-4b71-a026-9104eaf27d59"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Topiramate</h2>
<p class="First">Concomitant administration of valproic acid and topiramate has been associated with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with and without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> <span class="Italics">[see Contraindications and Warnings and Precautions <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4</a>, <a href="#i4i_section_id_5b1d0c1a-d6c2-4b72-b1fb-4a66491ba9c5">5.7</a>,<a href="#i4i_section_id_ab85a9ea-31b3-454f-bb81-5b63a5937f6e">5.8)</a>]</span>. <span class="Bold">Concomitant administration of topiramate with valproic acid has also been associated with <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> in patients who have tolerated either drug alone. It may be prudent to examine blood <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels in patients in whom the onset of <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> has been reported <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_5b1d0c1a-d6c2-4b72-b1fb-4a66491ba9c5">(5.7</a>, <a href="#i4i_section_id_fcfdd76e-e83d-4029-8b24-5e394b6669e2">5.9)</a>]</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_e9484c85-b037-4d65-9be9-be74078c54d4"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_6eb9713e-4a45-46f3-8e7f-2946dfc43733"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Teratogenic Effects: Pregnancy Category D.</p>
<p>Use of Depakote ER during pregnancy can cause congenital malformations including <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Depakote ER should be considered for women of childbearing potential only after the risks have been thoroughly discussed with the patient and weighed against the potential benefits of treatment.</p>
<p><span class="Underline">Human Data</span></p>
<p>Congenital Malformations</p>
<p>The North American Antiepileptic Drug Pregnancy Registry reported 16 cases of congenital malformations among the offspring of 149 women with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> who were exposed to valproic acid monotherapy during the first trimester of pregnancy at doses of approximately 1,000 mg per day, for a prevalence rate of 10.7% (95% CI 6.3%-16.9%). Three of the 149 offspring (2%) had <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> and 6 of the 149 (4%) had less severe malformations. Among epileptic women who were exposed to other antiepileptic drug monotherapies during pregnancy (1,048 patients) the malformation rate was 2.9% (95% CI 2.0% to 4.1%). There was a 4-fold increase in congenital malformations among infants with valproic acid-exposed mothers compared with those treated with other antiepileptic monotherapies as a group (Odds Ratio 4.0; 95% CI 2.1 to 7.4). This increased risk does not reflect a comparison versus any specific antiepileptic drug, but the risk versus the heterogeneous group of all other antiepileptic drug monotherapies combined. The increased teratogenic risk from valproic acid in women with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> is expected to be reflected in an increased risk in other indications (e.g., <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or bipolar disorder).</p>
<p>The strongest association of maternal valproate usage with congenital malformations is with <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> (as discussed under the next subheading). However, other congenital anomalies (e.g. craniofacial defects, cardiovascular malformations and anomalies involving various body systems), compatible and incompatible with life, have been reported. Sufficient data to determine the incidence of these congenital anomalies are not available.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">Neural Tube Defects</span></span></p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> in the fetus is increased in mothers receiving valproate during the first trimester of pregnancy. The Centers for Disease Control (CDC) has estimated the risk of valproic acid exposed women having children with <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> to be approximately 1 to 2%. The American College of Obstetricians and Gynecologists (ACOG) estimates the general population risk for congenital <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> as 0.14% to 0.2%.</p>
<p>Tests to detect neural tube and other defects using currently accepted procedures should be considered a part of routine prenatal care in pregnant women receiving valproate.</p>
<p>Evidence suggests that pregnant women who receive folic acid supplementation may be at decreased risk for congenital <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> in their offspring compared to pregnant women not receiving folic acid. Whether the risk of <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> in the offspring of women receiving valproate specifically is reduced by folic acid supplementation is unknown. Dietary folic acid supplementation both prior to and during pregnancy should be routinely recommended to patients contemplating pregnancy.</p>
<p><span class="Underline">Other Adverse Pregnancy Effects</span></p>
<p>Patients taking valproate may develop clotting abnormalities <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_100a0452-afcb-476f-bc60-34c271afa56e">(5.6)</a>]</span>. A patient who had low fibrinogen when taking multiple anticonvulsants including valproate gave birth to an infant with <span class="product-label-link" type="condition" conceptid="4083191" conceptname="Afibrinogenemia">afibrinogenemia</span> who subsequently died of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. If valproate is used in pregnancy, the clotting parameters should be monitored carefully. </p>
<p>Patients taking valproate may develop <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a>]</span>. Fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failures</span>, in a newborn and in an infant, have been reported following the maternal use of valproate during pregnancy.</p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delay</span>, <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autism</span> and/or <span class="product-label-link" type="condition" conceptid="439776" conceptname="Pervasive developmental disorder">autism spectrum disorder</span> in the offspring of women exposed to valproate during pregnancy.</p>
<p><span class="Underline">Animal Data</span></p>
<p>Reproduction studies have demonstrated valproate-induced <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Increased incidences of malformations, as well as <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been observed in mice, rats, rabbits, and monkeys following prenatal exposure to valproate. Malformations of the skeletal system are the most common structural abnormalities produced in experimental animals; however, neural tube closure defects were observed in mice exposed during organogenesis to maternal plasma valproate concentrations 2.3 times the upper limit of the human therapeutic range. </p>
<p>In pregnant rats, oral administration during organogenesis of a dose ≥0.5 times the maximum recommended daily human dose on a mg/m<span class="Sup">2</span> basis (MRHD) produced malformations (e.g. skeletal, cardiac, and urogenital) and <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span> in the offspring. These doses resulted in peak maternal plasma valproate levels of ≥3.4 times the upper limit of the human therapeutic range. Behavioral deficits have been reported in the offspring of rats given 0.5 times the MRHD on a mg/m<span class="Sup">2</span> basis throughout most of pregnancy.</p>
<p>Valproate produced skeletal and visceral malformations in the offspring of pregnant rabbits given an oral dose approximately 2 times the MRHD on a mg/m<span class="Sup">2</span> basis during organogenesis. Skeletal malformations, <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were observed in rhesus monkeys following an oral dose equal to the MRHD on a mg/m<span class="Sup">2</span> basis during organogenesis. This dose resulted in peak maternal plasma valproate levels 2.8 times the upper limit of the human therapeutic range.</p>
<p><span class="Italics">Registry</span></p>
<p>To provide information regarding the effects of in utero exposure to Depakote ER, healthcare providers are advised to recommend that pregnant patients taking Depakote ER enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_8f35e55e-e46c-4f8f-a466-3b0fd21d3667"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Valproate is excreted in breast milk. Concentrations in breast milk have been reported to be 1-10% of serum concentrations. Because of the potential for adverse reactions in a nursing infant, a decision between the physician and the patient should be made on whether to discontinue nursing or consider an alternative drug treatment for the mother, as appropriate.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_3bf472cd-2dc1-402c-a2ab-93a1a7904b94"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Depakote was studied in seven pediatric clinical trials. Two of the pediatric studies were placebo-controlled to evaluate the efficacy of Depakote ER for the indications of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (150 patients aged 10 to 17 years, 76 of whom were on Depakote ER) and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (304 patients aged 12 to 17 years, 231 of whom were on Depakote ER).</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p>A single 4-week outpatient, double-blind, placebo controlled study of 150 patients aged 10-17 years of age with pediatric bipolar disorder was conducted to evaluate the efficacy of Depakote ER in the treatment of pediatric bipolar disorder. Initial daily doses of 15mg/kg (max. 750mg/day) and flexible dosing was used to achieve a clinical response and/or a target serum valproate level of 80-125 mcg/ml with a maximum allowable dose set at 35mg/kg. Patients on stimulant medications at screening were allowed to continue and maintain current stimulant doses during the trial provided that doses were clinically stable. The trial efficacy endpoint was change from baseline on the YMRS scale at final visit.</p>
<p>Results from the trial revealed that the mean maximum daily dose of 1457 mg (27.1 mg/kg) with a mean final serum valproate concentration of 80 mcg/ml was attained in this clinical trial.</p>
<p>Efficacy was not established in this study.</p>
<p><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Prophylaxis</p>
<p>A single, double-blind, placebo-controlled, parallel-group, four equal armed (placebo, 250 mg, 500 mg and 1,000 mg) trial was performed to evaluate the efficacy of Depakote ER in adolescent patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (304 patients, ages 12-17 years old). The study consisted of a 4 week baseline period followed by a 12 week experimental period (including an initial 2 week titration phase). The primary endpoint was the reduction from baseline in the 4 week <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> rate. Placebo was compared to each dose.</p>
<p>Efficacy was not established in this <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> study.</p>
<p><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></p>
<p>Depakote ER has not been proven to be safe and effective for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> in children less than 10 years of age.</p>
<p><span class="Underline">Pediatric Safety</span></p>
<p>Two six-month pediatric studies were conducted to evaluate the long-term safety of Depakote ER in the indication of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (292 patients aged 10 to 17 years). Two twelve-month pediatric studies were conducted to evaluate the long-term safety of Depakote ER in the indication of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (353 patients aged 12 to 17 years). One twelve-month study was conducted to evaluate the safety of Depakote Sprinkles Capsules in the indication of <span class="product-label-link" type="condition" conceptid="4106574" conceptname="Partial seizure">partial seizures</span> (169 patients aged 3 to 10 years). </p>
<p><span class="Underline">Safety Studies-<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p><span class="Underline">Safety Study-Controlled <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Trial </span></p>
<p>The incidence of treatment-emergent events for the pediatric population was based on the data from the single placebo-controlled clinical trial of Depakote ER in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with bipolar disorder.</p>
<p>Table 8 includes those adverse reactions reported for pediatric patients in the placebo-controlled <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> trial where the incidence rate in the valproate-treated group was ≥5% and was at least twice the rate than that for placebo patients.</p>
<a name="id_f01bb837-6f97-4428-9f28-e7fde09735da"></a><table border="">
<caption><span>Table 8. Common, Drug-Related Adverse Reactions reported by ≥ 5% of Depakote-ER Treated Patients during Placebo Controlled Trials for Pediatric <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Acute Mania</span></span></caption>
<col width="97*">
<col width="98*">
<col width="101*">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"><span class="Bold">Adverse Reaction-preferred term </span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold"> Depakote ER <br> (n=76)</span></td>
<td align="center" valign="top"><span class="Bold">Placebo <br>(n=74)</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Toprule" align="center" valign="top">9%</td>
<td align="center" valign="top">1%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper abdominal Pain</span></td>
<td align="center" valign="top">8%</td>
<td align="center" valign="top">1%</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center" valign="top">7%</td>
<td align="center" valign="top">1%</td>
</tr>
<tr>
<td align="left" valign="top">Increased <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">Ammonia</span></td>
<td align="center" valign="top">5%</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span></td>
<td align="center" valign="top">5%</td>
<td align="center" valign="top">0</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="top">5%</td>
<td align="center" valign="top">1%</td>
</tr>
</tbody>
</table>
<p>In addition, patients taking Depakote ER had a statistically significant 1.5 lbs mean increase in weight and 0.4 unit BMI mean increase from baseline values over placebo treated patients. </p>
<p><span class="Underline">Safety Study-Open Label <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Safety Data</span></p>
<p>In the two long-term (six month) safety studies in pediatric patients (n= 292) between the ages of 10 and 17 years old, no clinically meaningful differences in the adverse reaction profile were observed when compared to adults.</p>
<p>The safety and tolerability of Depakote ER in pediatric patients were shown to be comparable to those in adults <span class="Italics">[see Adverse Reactions <a href="#i4i_section_id_066c5604-45d9-4fc2-9196-aa3908d63a1c">(6.1</a>, <a href="#i4i_section_id_f6d1420a-a44b-45db-a3d5-7b7ee467548d">6.2</a>, <a href="#i4i_section_id_45057023-a8ac-4a6e-9bb7-6f5cb805097c">6.3)</a>]</span>.</p>
<p><span class="Underline">Safety Studies-<span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> (open label)</span></p>
<p>Safety and tolerability in this study was found comparable to that observed in adult <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> studies.</p>
<p><span class="Underline">Safety Studies-<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> (controlled and open label)</span></p>
<p>Safety and tolerability in this study was found comparable to that observed in adult <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> studies. </p>
<p><span class="Underline">Prior Safety Experience</span></p>
<p>Experience has indicated that pediatric patients under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those with the aforementioned conditions<span class="Italics">[see <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">Boxed Warning</a>, Warnings and Precautions<a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a>]</span>. When valproic acid is used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. Above the age of 2 years, experience in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> has indicated that the incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.</p>
<p>The variability in free fraction limits the clinical usefulness of monitoring total serum valproic acid concentrations. Interpretation of valproic acid concentrations in children should include consideration of factors that affect hepatic metabolism and protein binding.</p>
<p>The safety and effectiveness of valproic acid for the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> has not been established in individuals below the age of 18 years.</p>
<p>The safety and effectiveness of valproic acid for the prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> has not been studied in individuals below the age of 12 years.</p>
<p><span class="Underline">Nonclinical Developmental Toxicology</span></p>
<p>The basic toxicology and pathologic manifestations of valproate sodium in neonatal (4-day old) and juvenile (14-day old) rats are similar to those seen in young adult rats. However, additional findings, including renal alterations in juvenile rats and renal alterations and retinal <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span> in neonatal rats, have been reported. These findings occurred at a dose approximately equal to the maximum recommended daily human dose (MRHD). They were not seen at a dose 0.4 times the MRHD.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_dfc5ccad-2126-451f-bae4-839d09a81781"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No patients above the age of 65 years were enrolled in double-blind prospective clinical trials of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> associated with bipolar illness. In a case review study of 583 patients, 72 patients (12%) were greater than 65 years of age. A higher percentage of patients above 65 years of age reported <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
<p>Discontinuation of valproate was occasionally associated with the latter two events. It is not clear whether these events indicate additional risk or whether they result from preexisting medical illness and concomitant medication use among these patients.</p>
<p>A study of elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> revealed drug related <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and discontinuation for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_8bf02a30-c935-4a01-b161-16abf6a30f7b">(5.12)</a>]</span>. The starting dose should be reduced in these patients, and dosage reductions or discontinuation should be considered in patients with excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <span class="Italics">[see Dosage and Administration <a href="#i4i_section_id_f7f54e6e-baec-4f76-974d-8297407462fb">(2.4)</a>]</span>.</p>
<p>There is insufficient information available to discern the safety and effectiveness of valproic acid for the prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> in patients over 65.</p>
<p>The capacity of elderly patients (age range: 68 to 89 years) to eliminate valproate has been shown to be reduced compared to younger adults (age range: 22 to 26 years) <span class="Italics">[see Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_ee4fa0c9-ba1b-4a6b-a720-f294d7f933ea">(12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_duplicate_id_c65533d3-8e3a-440c-97ba-3297d9df58dd"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Effect of Disease</h2>
<p class="First"><span class="Underline">Liver Disease</span></p>
<p><span class="Italics">[(See <a href="#i4i_warnings_precautions_id_6e218074-0906-4954-9177-d372e1c9c284">Boxed Warning</a>, Contraindications <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4)</a>, and Warnings and Precautions <a href="#i4i_warnings_precautions_id_6e218074-0906-4954-9177-d372e1c9c284">(5)</a> and Clinical Pharmacology <a href="#i4i_pharmacokinetics_id_ee4fa0c9-ba1b-4a6b-a720-f294d7f933ea">(12.3)</a>]</span>. Liver disease impairs the capacity to eliminate valproate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_e0fd201c-7455-4a2d-aaad-e24911f65f51"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Over dosage with valproate may result in <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, and deep <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Fatalities have been reported; however patients have recovered from valproate levels as high as 2120 mcg/mL. </p>
<p>In <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations, the fraction of drug not bound to protein is high and hemodialysis or tandem hemodialysis plus hemoperfusion may result in significant removal of drug. The benefit of gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> will vary with the time since ingestion. General supportive measures should be applied with particular attention to the maintenance of adequate urinary output.</p>
<p>Naloxone has been reported to reverse the CNS depressant effects of valproate over dosage. Because naloxone could theoretically also reverse the antiepileptic effects of valproate, it should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_8af34b3e-12bf-4a88-9274-036ba34cad3d"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure: </p>
<div class="Figure">
<img alt="Chemical structure of divalproex sodium" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3f7c414-db83-4a7a-a7aa-745c5606cdba&amp;name=eb0bf16b-8747-4070-baaa-d32085cb029f-01.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Divalproex sodium occurs as a white powder with a characteristic odor.</p>
<p>Depakote ER 250 and 500 mg tablets are for oral administration. Depakote ER tablets contain divalproex sodium in a once-a-day extended-release formulation equivalent to 250 and 500 mg of valproic acid.</p>
<p>Inactive Ingredients</p>
<p>Depakote ER 250 and 500 mg tablets: FD&amp;C Blue No. 1, hypromellose, lactose, microcrystalline cellulose, polyethylene glycol, potassium sorbate, propylene glycol, silicon dioxide, titanium dioxide, and triacetin. </p>
<p>In addition, 500 mg tablets contain iron oxide and polydextrose. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_fc7365a7-0afa-49e5-bdff-ffc612bdb390"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_ea50a72e-b684-40db-83b9-093eb7e152ae"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Divalproex sodium dissociates to the valproate ion in the gastrointestinal tract. The mechanisms by which valproate exerts its therapeutic effects have not been established. It has been suggested that its activity in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> is related to increased brain concentrations of gamma-aminobutyric acid (GABA).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_093f72f5-4852-42e5-85db-e4ac805f415a"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The relationship between plasma concentration and clinical response is not well documented. One contributing factor is the nonlinear, concentration dependent protein binding of valproate which affects the clearance of the drug. Thus, monitoring of total serum valproate may not provide a reliable index of the bioactive valproate species as protein binding may be affected by age and disease state (e.g. hepatic or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></span></p>
<p>The therapeutic range in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> is commonly considered to be 50 to 100 mcg/mL of total valproate, although some patients may be controlled with lower or higher plasma concentrations.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p>In placebo-controlled clinical trials of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span>, patients were dosed to clinical response with trough plasma concentrations between 85 and 125 mcg/mL <span class="Italics">[see Dosage and Administration <a href="#i4i_section_id_344c0a99-70a3-4597-aabb-d4b6b2acbbd3">(2.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_ee4fa0c9-ba1b-4a6b-a720-f294d7f933ea"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption/Bioavailability</span></p>
<p>The absolute bioavailability of Depakote ER tablets administered as a single dose after a meal was approximately 90% relative to intravenous infusion. </p>
<p>When given in equal total daily doses, the bioavailability of Depakote ER is less than that of Depakote (divalproex sodium delayed-release tablets). In five multiple-dose studies in healthy subjects (N=82) and in subjects with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (N=86), when administered under fasting and nonfasting conditions, Depakote ER given once daily produced an average bioavailability of 89% relative to an equal total daily dose of Depakote given BID, TID, or QID. The median time to maximum plasma valproate concentrations (C<span class="Sub">max</span>) after Depakote ER administration ranged from 4 to 17 hours. After multiple once-daily dosing of Depakote ER, the peak-to-trough fluctuation in plasma valproate concentrations was 10-20% lower than that of regular Depakote given BID, TID, or QID.</p>
<p><span class="Bold">Conversion from Depakote to Depakote ER</span></p>
<p>When Depakote ER is given in doses 8 to 20% higher than the total daily dose of Depakote, the two formulations are bioequivalent. In two randomized, crossover studies, multiple daily doses of Depakote were compared to 8 to 20% higher once-daily doses of Depakote ER. In these two studies, Depakote ER and Depakote regimens were equivalent with respect to area under the curve (AUC; a measure of the extent of bioavailability). Additionally, valproate C<span class="Sub">max</span> was lower, and C<span class="Sub">min</span> was either higher or not different, for Depakote ER relative to Depakote regimens (see Table 9). </p>
<a name="id_2059b2a2-44e1-4d3e-b797-0ea8708bb9d2"></a><table>
<caption><span>Table 9. Bioavailability of Depakote ER Tablets Relative to Depakote When Depakote ER Dose is 8 to 20% Higher</span></caption>
<col width="22%">
<col width="26%">
<col width="18%">
<col width="16%">
<col width="15%">
<thead>
<tr class="First Toprule">
<td align="left" valign="top">
<br><span class="Bold">Study Population </span>
</td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Regimens</span></td>
<td align="center" colspan="3" valign="top"><span class="Bold">Relative Bioavailability</span></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">Depakote ER vs. Depakote</td>
<td class="Botrule" align="center" valign="top">AUC<span class="Sub">24</span>
</td>
<td class="Botrule" align="center" valign="top">C<span class="Sub">max</span>
</td>
<td align="center" valign="top">C<span class="Sub">min</span>
</td>
</tr>
</thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Healthy Volunteers (N=35)</td>
<td class="Toprule" align="center" valign="top">1000 &amp; 1500 mg<br>Depakote ER vs.<br>875 &amp; 1250 mg Depakote</td>
<td class="Toprule" align="center" valign="top">1.059</td>
<td class="Toprule" align="center" valign="top">0.882</td>
<td align="center" valign="top">1.173</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> on concomitant enzyme-inducing antiepilepsy drugs (N = 64)</td>
<td align="center" valign="top">1000 to 5000 mg<br>Depakote ER vs.<br>875 to 4250 mg<br>Depakote</td>
<td align="center" valign="top">1.008</td>
<td align="center" valign="top">0.899</td>
<td align="center" valign="top">1.022</td>
</tr>
</tbody>
</table>
<p>Concomitant antiepilepsy drugs (topiramate, phenobarbital, carbamazepine, phenytoin, and lamotrigine were evaluated) that induce the cytochrome P450 isozyme system did not significantly alter valproate bioavailability when converting between Depakote and Depakote ER. </p>
<p><span class="Underline">Distribution</span></p>
<p><span class="Italics">Protein Binding</span></p>
<p>The plasma protein binding of valproate is concentration dependent and the free fraction increases from approximately 10% at 40 mcg/mL to 18.5% at 130 mcg/mL. Protein binding of valproate is reduced in the elderly, in patients with chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic diseases</span>, in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and in the presence of other drugs (e.g., aspirin). Conversely, valproate may displace certain protein-bound drugs (e.g., phenytoin, carbamazepine, warfarin, and tolbutamide) <span class="Italics">[see Drug Interactions <a href="#i4i_interactions_id_c6b6e770-d94f-4e73-b606-81a1bfe5c579">(7)</a></span> for more detailed information on the <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> of valproate with other drugs].</p>
<p><span class="Italics">CNS Distribution</span></p>
<p>Valproate concentrations in cerebrospinal fluid (CSF) approximate unbound concentrations in plasma (about 10% of total concentration).</p>
<p><span class="Underline">Metabolism</span></p>
<p>Valproate is metabolized almost entirely by the liver. In adult patients on monotherapy, 30-50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial β-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15-20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine.</p>
<p>The relationship between dose and total valproate concentration is nonlinear; concentration does not increase proportionally with the dose, but rather, increases to a lesser extent due to saturable plasma protein binding. The kinetics of unbound drug are linear.</p>
<p><span class="Underline">Elimination</span></p>
<p>Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m<span class="Sup">2 </span>and 11 L/1.73 m<span class="Sup">2</span>, respectively. Mean plasma clearance and volume of distribution for free valproate are 4.6 L/hr/1.73 m<span class="Sup">2</span> and 92 L/1.73 m<span class="Sup">2</span>. Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1000 mg.</p>
<p>The estimates cited apply primarily to patients who are not taking drugs that affect hepatic metabolizing enzyme systems. For example, patients taking enzyme-inducing antiepileptic drugs (carbamazepine, phenytoin, and phenobarbital) will clear valproate more rapidly. Because of these changes in valproate clearance, monitoring of antiepileptic concentrations should be intensified whenever concomitant antiepileptics are introduced or withdrawn.</p>
<p><span class="Underline">Special Populations</span></p>
<p><span class="Italics">Effect of Age</span></p>
<p>Pediatric</p>
<p>The valproate pharmacokinetic profile following administration of Depakote ER was characterized in a multiple-dose, non-fasting, open label, multi-center study in children and adolescents. Depakote ER once daily doses ranged from 250-1750 mg. Once daily administration of Depakote ER in pediatric patients (10-17 years) produced plasma VPA concentration-time profiles similar to those that have been observed in adults.</p>
<p>Elderly</p>
<p>The capacity of elderly patients (age range: 68 to 89 years) to eliminate valproate has been shown to be reduced compared to younger adults (age range: 22 to 26). Intrinsic clearance is reduced by 39%; the free fraction is increased by 44%. Accordingly, the initial dosage should be reduced in the elderly <span class="Italics">[see Dosage and Administration <a href="#i4i_section_id_f7f54e6e-baec-4f76-974d-8297407462fb">(2.4)</a>]</span>.</p>
<p><span class="Italics">Effect of Sex</span></p>
<p>There are no differences in the body surface area adjusted unbound clearance between males and females (4.8±0.17 and 4.7±0.07 L/hr per 1.73 m<span class="Sup">2</span>, respectively).</p>
<p><span class="Italics">Effect of Race</span></p>
<p>The effects of race on the kinetics of valproate have not been studied.</p>
<p><span class="Italics">Effect of Disease</span></p>
<p>Liver Disease</p>
<p>Liver disease impairs the capacity to eliminate valproate. In one study, the clearance of free valproate was decreased by 50% in 7 patients with cirrhosis and by 16% in 4 patients with acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, compared with 6 healthy subjects. In that study, the half-life of valproate was increased from 12 to 18 hours. Liver disease is also associated with decreased albumin concentrations and larger unbound fractions (2 to 2.6 fold increase) of valproate. Accordingly, monitoring of total concentrations may be misleading since free concentrations may be substantially elevated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> whereas total concentrations may appear to be normal <span class="Italics">[see <a href="#i4i_warnings_precautions_id_6e218074-0906-4954-9177-d372e1c9c284">Boxed Warning</a>, Contraindications <a href="#i4i_contraindications_id_a1c71cb9-749e-445d-b924-d4a04fea0981">(4)</a>, Warnings and Precautions <a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a>]</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></p>
<p>A slight reduction (27%) in the unbound clearance of valproate has been reported in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (creatinine clearance &lt; 10 mL/minute); however, hemodialysis typically reduces valproate concentrations by about 20%. Therefore, no dosage adjustment appears to be necessary in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Protein binding in these patients is substantially reduced; thus, monitoring total concentrations may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_27372253-30b8-40de-85fa-c6e08bbd16e5"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_aaacad09-0f4a-4d17-9861-7cde12c957b6"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Valproic acid was administered orally to Sprague Dawley rats and ICR (HA/ICR) mice at doses of 80 and 170 mg/kg/day (approximately 10 to 50% of the maximum human daily dose on a mg/m<span class="Sup">2</span> basis) for two years. A variety of neoplasms were observed in both species. The primary findings were a statistically significant increase in the incidence of subcutaneous <span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcomas</span> in high dose male rats receiving valproic acid and a statistically significant dose-related trend for benign pulmonary <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in male mice receiving valproic acid. The significance of these findings for humans is unknown.</p>
<p><span class="Underline">Mutagenesis</span></p>
<p>Valproate was not mutagenic in an <span class="Italics">in vitro</span> bacterial assay (Ames test), did not produce dominant lethal effects in mice, and did not increase chromosome aberration frequency in an in vivo cytogenetic study in rats. Increased frequencies of sister chromatid exchange (SCE) have been reported in a study of epileptic children taking valproate, but this association was not observed in another study conducted in adults. There is some evidence that increased SCE frequencies may be associated with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. The biological significance of an increase in SCE frequency is not known.</p>
<p><span class="Underline">Fertility</span></p>
<p>Chronic toxicity studies in juvenile and adult rats and dogs demonstrated reduced spermatogenesis and <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> at oral doses of 400 mg/kg/day or greater in rats (approximately equivalent to or greater than the maximum human daily dose (MHD) on a mg/m<span class="Sup">2</span> basis) and 150 mg/kg/day or greater in dogs (approximately 1.4 times the MHD or greater on a mg/m<span class="Sup">2</span> basis). Fertility studies in rats have shown doses up to 350 mg/kg/day (approximately equal to the MHD on a mg/m<span class="Sup">2</span> basis) for 60 days to have no effect on fertility. The effect of valproate on testicular development and on sperm production and fertility in humans is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_cef20761-dd4e-4a3e-abab-6920021b247a"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1031f88f-96df-47bf-9821-4a804331ea0e"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></h2>
<p class="First">The effectiveness of Depakote ER for the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> is based in part on studies establishing the effectiveness of Depakote (divalproex sodium delayed release tablets) for this indication. Depakote ER’s effectiveness was confirmed in one randomized, double-blind, placebo-controlled, parallel group, 3-week, multicenter study. The study was designed to evaluate the safety and efficacy of Depakote ER in the treatment of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed type, in adults. Adult male and female patients who had a current DSM-IV TR primary diagnosis of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed type, and who were hospitalized for <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span>, were enrolled into this study. Depakote ER was initiated at a dose of 25 mg/kg/day given once daily, increased by 500 mg/day on Day 3, then adjusted to achieve plasma valproate concentrations in the range of 85-125 mcg/mL. Mean daily Depakote ER doses for observed cases were 2362 mg (range: 500-4000), 2874 mg (range: 1500-4500), 2993 mg (range: 1500-4500), 3181 mg (range: 1500-5000), and 3353 mg (range: 1500-5500) at Days 1, 5, 10, 15, and 21, respectively. Mean valproate concentrations were 96.5 mcg/mL, 102.1 mcg/mL, 98.5 mcg/mL, 89.5 mcg/mL at Days 5, 10, 15 and 21, respectively. Patients were assessed on the <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Rating Scale (MRS; score ranges from 0-52). </p>
<p>Depakote ER was significantly more effective than placebo in reduction of the MRS total score.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93c9844f-47fd-4b5b-8c25-8e5c9ff1d27e"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">The efficacy of valproate in reducing the incidence of <span class="product-label-link" type="condition" conceptid="4236312" conceptname="Complex partial epileptic seizure">complex partial seizures</span> (CPS) that occur in isolation or in association with other <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> types was established in two controlled trials.</p>
<p>In one, multiclinic, placebo controlled study employing an add-on design, (adjunctive therapy) 144 patients who continued to suffer eight or more CPS per 8 weeks during an 8 week period of monotherapy with doses of either carbamazepine or phenytoin sufficient to assure plasma concentrations within the "therapeutic range" were randomized to receive, in addition to their original antiepilepsy drug (AED), either Depakote or placebo. Randomized patients were to be followed for a total of 16 weeks. The following Table presents the findings.</p>
<a name="id_a6391053-12b3-44da-975f-8f7701eb78c8"></a><table>
<caption><span>Table 10. Adjunctive Therapy Study Median Incidence of CPS per 8 Weeks</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"><span class="Bold">Add-on <br>Treatment</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Number <br>of Patients</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Baseline <br>Incidence</span></td>
<td align="center" valign="top"><span class="Bold">Experimental <br>Incidence</span></td>
</tr></thead>
<tfoot><tr class="Last"><td align="left" colspan="4" valign="top"><p class="First">*   Reduction from baseline statistically significantly greater for valproate than placebo at p ≤ 0.05 level.</p></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Depakote</td>
<td class="Toprule" align="center" valign="top">75</td>
<td class="Toprule" align="center" valign="top">16.0</td>
<td align="center" valign="top">8.9*</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Placebo</td>
<td align="center" valign="top">69</td>
<td align="center" valign="top">14.5</td>
<td align="center" valign="top">11.5</td>
</tr>
</tbody>
</table>
<p>Figure 1 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates was at least as great as that indicated on the Y axis in the adjunctive therapy study. A positive percent reduction indicates an improvement (i.e., a decrease in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for an effective treatment is shifted to the left of the curve for placebo. This Figure shows that the proportion of patients achieving any particular level of improvement was consistently higher for valproate than for placebo. For example, 45% of patients treated with valproate had a ≥ 50% reduction in complex partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rate compared to 23% of patients treated with placebo.</p>
<p> Figure 1 </p>
<div class="Figure">
<img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3f7c414-db83-4a7a-a7aa-745c5606cdba&amp;name=eb0bf16b-8747-4070-baaa-d32085cb029f-02.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>The second study assessed the capacity of valproate to reduce the incidence of CPS when administered as the sole AED. The study compared the incidence of CPS among patients randomized to either a high or low dose treatment arm. Patients qualified for entry into the randomized comparison phase of this study only if 1) they continued to experience 2 or more CPS per 4 weeks during an 8 to 12 week long period of monotherapy with adequate doses of an AED (i.e., phenytoin, carbamazepine, phenobarbital, or primidone) and 2) they made a successful transition over a two week interval to valproate. Patients entering the randomized phase were then brought to their assigned target dose, gradually tapered off their concomitant AED and followed for an interval as long as 22 weeks. Less than 50% of the patients randomized, however, completed the study. In patients converted to Depakote monotherapy, the mean total valproate concentrations during monotherapy were 71 and 123 mcg/mL in the low dose and high dose groups, respectively. </p>
<p>The following Table presents the findings for all patients randomized who had at least one post-randomization assessment.</p>
<a name="id_adb8e4b1-c28a-4877-8018-9740ad416dd9"></a><table>
<caption><span>Table 11. Monotherapy Study Median Incidence of CPS per 8 Weeks</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<thead><tr class="Botrule First Last">
<td align="left" valign="top"><span class="Bold">Treatment</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Number <br>of Patients</span></td>
<td class="Toprule" align="center" valign="top"><span class="Bold">Baseline <br>Incidence</span></td>
<td align="center" valign="top"><span class="Bold">Randomized <br>Phase Incidence</span></td>
</tr></thead>
<tfoot><tr class="Last"><td align="left" colspan="4" valign="top"><p class="First">*   Reduction from baseline statistically significantly greater for high dose than low dose at p ≤ 0.05 level.</p></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">High dose Valproate</td>
<td class="Toprule" align="center" valign="top">131</td>
<td class="Toprule" align="center" valign="top">13.2</td>
<td align="center" valign="top">10.7*</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Low dose Valproate</td>
<td align="center" valign="top">134</td>
<td align="center" valign="top">14.2</td>
<td align="center" valign="top">13.8</td>
</tr>
</tbody>
</table>
<p>Figure 2 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates was at least as great as that indicated on the Y axis in the monotherapy study. A positive percent reduction indicates an improvement (i.e., a decrease in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency), while a negative percent reduction indicates worsening. Thus, in a display of this type, the curve for a more effective treatment is shifted to the left of the curve for a less effective treatment. This Figure shows that the proportion of patients achieving any particular level of reduction was consistently higher for high dose valproate than for low dose valproate. For example, when switching from carbamazepine, phenytoin, phenobarbital or primidone monotherapy to high dose valproate monotherapy, 63% of patients experienced no change or a reduction in complex partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates compared to 54% of patients receiving low dose valproate.</p>
<p> Figure 2 </p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3f7c414-db83-4a7a-a7aa-745c5606cdba&amp;name=eb0bf16b-8747-4070-baaa-d32085cb029f-03.jpg"></p>
<p>Information on pediatric studies are presented in section 8.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8c356c2-2f41-4c41-9d4f-2fe0065c8386"></a><a name="section-13.3"></a><p></p>
<h2>14.3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">The results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial demonstrated the effectiveness of Depakote ER in the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. This trial recruited patients with a history of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> occurring on average twice or more a month for the preceding three months. Patients with cluster or chronic daily <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> were excluded. Women of childbearing potential were allowed in the trial if they were deemed to be practicing an effective method of contraception. </p>
<p>Patients who experienced ≥ 2 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> in the 4-week baseline period were randomized in a 1:1 ratio to Depakote ER or placebo and treated for 12 weeks. Patients initiated treatment on 500 mg once daily for one week, and were then increased to 1000 mg once daily with an option to permanently decrease the dose back to 500 mg once daily during the second week of treatment if intolerance occurred. Ninety-eight of 114 Depakote ER-treated patients (86%) and 100 of 110 placebo-treated patients (91%) treated at least two weeks maintained the 1000 mg once daily dose for the duration of their treatment periods. Treatment outcome was assessed on the basis of reduction in 4-week <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> rate in the treatment period compared to the baseline period. </p>
<p>Patients (50 male, 187 female) ranging in age from 16 to 69 were treated with Depakote ER (N=122) or placebo (N=115). Four patients were below the age of 18 and 3 were above the age of 65. Two hundred and two patients (101 in each treatment group) completed the treatment period. The mean reduction in 4-week <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> rate was 1.2 from a baseline mean of 4.4 in the Depakote ER group, versus 0.6 from a baseline mean of 4.2 in the placebo group. The treatment difference was statistically significant (see Figure 3).</p>
<p> Figure 3 Mean Reduction In 4-Week <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine Headache</span> Rates </p>
<p><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3f7c414-db83-4a7a-a7aa-745c5606cdba&amp;name=eb0bf16b-8747-4070-baaa-d32085cb029f-04.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_5f81fd86-9b97-478e-910a-9f2834fcea8f"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Depakote ER 250 mg is available as white ovaloid tablets with the corporate Abbott “A? logo , and the Abbo-Code (HF). Each Depakote ER tablet contains divalproex sodium equivalent to 250 mg of valproic acid in the following package sizes:</p>
<p>Bottles of 60....……………………………………………(NDC 0074-3826-60).</p>
<p>Bottles of 100……………………………………………..(NDC 0074-3826-13).</p>
<p>Bottles of 500……………………………………………..(NDC 0074-3826-53).</p>
<p>ABBO-PAC unit dose packages of 100…………………..(NDC 0074-3826-11).</p>
<p>Depakote ER 500 mg is available as gray ovaloid tablets with the corporate Abbott “A? logo, and the Abbo-Code HC. Each Depakote ER tablet contains divalproex sodium equivalent to 500 mg of valproic acid in the following packaging sizes:</p>
<p>Bottles of 100....................................................................(NDC 0074-7126-13).</p>
<p>Bottles of 500....................................................................(NDC 0074-7126-53).</p>
<p>ABBO-PAC unit dose packages of 100............................(NDC 0074-7126-11).</p>
<p>Recommended Storage</p>
<p>Store tablets at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_5a8b54cd-de98-4bfc-84c6-47c418a856f0"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_630d1115-05dc-4b8b-90ba-f562f5a26788"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Hepatotoxicity</h2>
<p class="First">Patients and guardians should be warned that <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and/or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> can be symptoms of hepatotoxicity and, therefore, require further medical evaluation promptly <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_c3620090-c486-4c33-a96a-1498c0247c30">(5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a112f6ab-830a-4d50-a386-e8a71c8c4a6f"></a><a name="section-15.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First">Patients and guardians should be warned that <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and/or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> can be symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and, therefore, require further medical evaluation promptly <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_87295897-6c45-4b22-a936-09cfdc513705">(5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f90c172-2394-4794-9ea3-e40e542ef6d2"></a><a name="section-15.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span>/Usage in Pregnancy</h2>
<p class="First">Use of valproate during pregnancy increases the risk for <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span> and other malformations. Female patients of child-bearing age, who require therapy for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, bipolar disorder, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>, should be advised of the risks of valproate use during pregnancy and appropriate therapeutic options. This is particularly important when the treatment of a spontaneously reversible condition not ordinarily associated with permanent injury or risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (e.g. <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>) is considered. Patients should read the Patient Information Leaflet, which appears as the last section of the labeling <span class="Italics">[see Use in Specific Populations <a href="#i4i_pregnancy_id_6eb9713e-4a45-46f3-8e7f-2946dfc43733">(8.1)</a>]</span>.</p>
<p>Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 <span class="Italics">[see Use in Specific Populations <a href="#i4i_pregnancy_id_6eb9713e-4a45-46f3-8e7f-2946dfc43733">(8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba89ddf0-4ac6-4a5d-ab09-9b9d71db4d58"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Suicidal Thinking and Behavior</h2>
<p class="First">Patients, their caregivers, and families should be counseled that AEDs, including Depakote ER, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to the healthcare providers <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_9de861e6-1f23-489c-807a-c5dbf0c6dce2">(5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_48e95652-f3b6-449e-86ed-7c2b2759054f"></a><a name="section-15.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></h2>
<p class="First">Patients should be informed of the signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> and be told to inform the prescriber if any of these symptoms occur <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_5b1d0c1a-d6c2-4b72-b1fb-4a66491ba9c5">(5.7</a>, <a href="#i4i_section_id_ab85a9ea-31b3-454f-bb81-5b63a5937f6e">5.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2995d701-43e1-41c7-ae45-22f0a027d103"></a><a name="section-15.6"></a><p></p>
<h2>17.6 <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span></h2>
<p class="First">Since valproate products may produce <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, especially when combined with another CNS depressant (e.g., alcohol), patients should be advised not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_92de15ea-d817-48f9-805b-f954a6ee2d3e"></a><a name="section-15.7"></a><p></p>
<h2>17.7 Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></h2>
<p class="First">Patients should be instructed that a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> associated with other organ system involvement (<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, etc.) may be drug-related and should be reported to the physician immediately <span class="Italics">[see Warnings and Precautions <a href="#i4i_section_id_b7fc40ba-4036-4906-9b88-ee178b8889fa">(5.10)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_df25463d-d77f-4d21-968e-230006bfc0d3"></a><a name="section-16"></a><p></p>
<h1>FDA–APPROVED PATIENT LABELING</h1>
<p class="First"><span class="Bold">Important Information for Women Who Could Become Pregnant About the Use of Depakote ER (divalproex sodium) extended release tablets.</span></p>
<p>Please read this leaflet carefully before you take any of this medication. This leaflet provides a summary of important information about taking this medication to women who could become pregnant. If you have any questions or concerns, or want more information about this medication, contact your doctor or pharmacist.</p>
<p><span class="Underline">Information For Women Who Could Become Pregnant</span></p>
<p>You can only obtain this medication by prescription from your doctor. The decision to use this medicine should be made by you and your doctor based on your health needs and medical condition.</p>
<p>Before starting this medicine, you should know that using this medicine during pregnancy causes an increased chance of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in your baby. These <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> may include <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span> and other defects where the spinal canal does not close normally. These defects usually occur in 1 to 2 out of every 1000 babies born in the United States. Studies show that for babies born to epileptic women who took valproate in the first 12 weeks of pregnancy, these defects occur in 1 to 2 out of every 100 babies. </p>
<p>Use of valproate during pregnancy also increases the chance of other <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> such as of the heart, bones, and other parts of the body. Studies suggest that other medicines used to treat your condition may be less likely to cause these defects.</p>
<p><span class="Underline">Information For Women Who Are Planning to Get Pregnant</span></p>
<p>Women using valproate who plan to get pregnant should discuss their treatment options with their doctor.</p>
<p><span class="Underline">Information For Women Who Become Pregnant</span></p>
<p>If you become pregnant while taking valproate, you should contact your doctor immediately. </p>
<p><span class="Underline">Other Important Information</span></p>
<ul>
<li>You should take your medicine exactly as prescribed by your doctor to get the most benefit from your medicine and reduce the risk of side effects. </li>
<li>If you have taken more than the prescribed dose, contact your hospital emergency room or local poison center immediately. </li>
<li>Your medicine was prescribed for your particular condition. Do not use it for another condition or give the drug to others. </li>
</ul>
<p><span class="Underline">Facts About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span></span></p>
<p>It is important to know that <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> may occur even in children born to women who are not taking any medicines and do not have other risk factors.</p>
<p>This summary provides important information about the use of Depakote ER (divalproex sodium) extended release tablets to women who could become pregnant. If you would like more information, ask your doctor or pharmacist to let you read the professional labeling and then discuss it with them. If you have any questions or concerns about taking this medication, you should discuss them with your doctor.</p>
<p>Revised: June, 2010</p>
<p><span class="Bold">Depakote ER 250 mg</span></p>
<p>Mfd. by Abbott Pharmaceuticals PR Ltd., Barceloneta, PR 00617</p>
<p><span class="Bold">Depakote ER 500 mg</span></p>
<p>Mfd. by</p>
<p>Abbott Laboratories, North Chicago, IL 60064 U.S.A.</p>
<p>or</p>
<p>Abbott Pharmaceuticals PR Ltd., Barceloneta, PR 00617</p>
<p>Manufactured for</p>
<p>Abbott Laboratories</p>
<p>North Chicago, IL 60064 U.S.A.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d9953f73-7bd1-4818-9046-69b3e20d992a"></a><a name="section-17"></a><p></p>
<h1>Principal display panel - 500 mg bag</h1>
<p class="First">Depakote   ER 500 MG VALPROIC ACID ACTIVITY</p>
<p>Divalproex Sodium Extended-Release Tablets</p>
<p>10 Tablets</p>
<div class="Figure"><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3f7c414-db83-4a7a-a7aa-745c5606cdba&amp;name=eb0bf16b-8747-4070-baaa-d32085cb029f-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEPAKOTE 		
					</strong><br><span class="contentTableReg">divalproex sodium tablet, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-2359(NDC:0074-7126)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DIVALPROEX SODIUM</strong> (VALPROIC ACID) </td>
<td class="formItem">VALPROIC ACID</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM SORBATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>AMMONIUM LAURETH-5 SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GRAY</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (ovaloid) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">HC</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-2359-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021168</td>
<td class="formItem">06/07/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-2359)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>eb0bf16b-8747-4070-baaa-d32085cb029f</div>
<div>Set id: d3f7c414-db83-4a7a-a7aa-745c5606cdba</div>
<div>Version: 2</div>
<div>Effective Time: 20120801</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
